

chain nodes :

6 12 15 17 24 25 27 28 29

ring nodes :

1 2 3 4 5 7 8 9 10 11 18 19 20 21 22 23

chain bonds :

4-6 6-7 9-12 10-15 17-27 18-29 22-25 23-24 27-28 28-29

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11 18-23 18-19 19-20 20-21 21-22 22-23

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15 17-27 18-23 18-19 18-29 19-20 20-21 21-22 22-23 22-25 23-24 27-28 28-29

exact bonds :

6-7

G1:Ph,Cy

G2:C,O,S,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:CLASS 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom  
24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS


L1 STR



G1 Ph,Cy  
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>  
Uploading C:\Program Files\Stnexp\Queries\10671326amendG.str



chain nodes :  
6 12 15 17 18 25 26  
ring nodes :  
1 2 3 4 5 7 8 9 10 11 19 20 21 22 23 24

chain bonds :

4-6 6-7 9-12 10-15 17-18 18-19 23-26 24-25

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11 19-20 19-24 20-21 21-22 22-23  
23-24

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15 17-18 18-19  
19-20 19-24 20-21 21-22 22-23 23-24 23-26 24-25

exact bonds :

6-7

G1:Ph,Cy

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:CLASS 15:CLASS 17:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom  
24:Atom 25:CLASS 26:CLASS 27:CLASS

L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS

L2 STR





G1 Ph,Cy

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10671326amend2.str



chain nodes :

6 12 15

ring nodes :

1 2 3 4 5 7 8 9 10 11

chain bonds :

4-6 6-7 9-12 10-15

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15

exact bonds :

6-7

G1:Ph,Cy

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:CLASS 15:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



G1 Ph,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:51:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5 TO 234  
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1

=> s l1 full  
FULL SEARCH INITIATED 10:51:15 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 119 TO ITERATE

100.0% PROCESSED 119 ITERATIONS 24 ANSWERS  
SEARCH TIME: 00.00.01

L5 24 SEA SSS FUL L1

=> s l2  
SAMPLE SEARCH INITIATED 10:51:25 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 4 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5 TO 234  
PROJECTED ANSWERS: 4 TO 200

L6 4 SEA SSS SAM L2

=> s l2 full  
FULL SEARCH INITIATED 10:51:30 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 121 TO ITERATE

100.0% PROCESSED 121 ITERATIONS 76 ANSWERS  
SEARCH TIME: 00.00.01

L7 76 SEA SSS FUL L2

=> s l3  
SAMPLE SEARCH INITIATED 10:51:42 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 41 TO ITERATE

100.0% PROCESSED 41 ITERATIONS 38 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 436 TO 1204  
PROJECTED ANSWERS: 391 TO 1129

L8 38 SEA SSS SAM L3

=> s l3 full  
FULL SEARCH INITIATED 10:51:48 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 861 TO ITERATE

100.0% PROCESSED 861 ITERATIONS 831 ANSWERS  
SEARCH TIME: 00.00.01

L9 831 SEA SSS FUL L3

=> fil hcaplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
484.85	485.06

FILE 'HCAPLUS' ENTERED AT 10:52:02 ON 29 NOV 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2005 VOL 143 ISS 23  
FILE LAST UPDATED: 28 Nov 2005 (20051128/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5  
L10 1 L5  
=> d ed abs ibib hitstr

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
ED Entered STN: 09 Apr 2004  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention provides a family of bifunctional heterocyclic compds., e.g., I (A = C, C(=O), N (with proviso, that at least one A = C); B = O, NR2, S(O), C(=O), C(=S), C(=NR3); p = 0, 1; q = 0, 1; r = 0 - 2; R2 = H, S(O)R4, CHO, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR2R2 = 5 to 8-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R3 = H, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR3R3 = 5 to (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NHCO3, C(=O)NR3R3, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, etc.; D = D1, D2, D3, D4; E = di- or penta-substituted Ph, substituted 4-vinylphenyl; G = C1-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C,N,O,S; dashed line = single or double bond) or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as anti-infective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional heterocyclic compds., and methods of using such compds. as anti-infective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin derivative II was prepared from N-(desmethylethylerythromycin), via N-alkylation with HC.tplbond.CCH2CH2OTf, and cycloaddn. with azide III.


ACCESSION NUMBER: 2004:292029 HCAPLUS  
DOCUMENT NUMBER: 140:321158  
TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as anti-infective, antiproliferative, antiinflammatory and prokinetic agents  
INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelere, Adesboyesa E.; Mcconell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.  
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 363 pp.  
DOCUMENT TYPE: CODEN: PIXXD2  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: English  
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030925
WO 2004029066	C1	20040513		
WO 2004029066	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B




RN 677726-86-2 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 677726-16-8P 677726-18-0P 677726-28-2P

Page 929/11/2005

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GT, ML, MR, NE, SH, TD, TG  
US 2005197334 A1 20050908 US 2003-671326 20030925  
CA 2500158 AA 20040408 CA 2003-2500158 20030926  
EP 1543017 A2 20050622 EP 2003-770506 20030926  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
PRIORITY APPLN. INFO.: US 2002-414207P P 20020926  
US 2003-448216P P 20030219  
WO 2003-US30478 W 20030925

OTHER SOURCE(S): MARPAT 140:321158  
IT 677726-85-1P 677726-86-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation and hydrolysis of; preparation of bifunctional heterocyclic compds.

for use as anti-infective, antiproliferative, antiinflammatory and prokinetic agents)  
RN 677726-85-1 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



540/454

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


677726-77-1P 677726-78-2P 677726-79-3P  
677726-80-6P 677726-82-8P 677726-87-3P  
677726-88-4P 677727-78-5P 677727-79-6P  
677727-80-9P 677727-81-0P 677727-82-1P  
677727-83-2P 677727-90-1P 677727-92-3P  
677727-95-6P 677727-96-7P 677727-97-8P  
677727-99-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of bifunctional heterocyclic compds. for use as anti-infective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-16-8 HCAPLUS  
CN Erythromycin, N-demethyl-N-[3-[[1-[[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




544/137

514/236.2

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A




RN 677726-18-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl)methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-A



PAGE 1-B

RN 677726-28-2 HCAPLUS  
 CN Erythromycin, N-[3-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]-N-demethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A



RN 677726-77-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[4-[1-[[[(5R)-2-oxo-3-(5-quinoliny)-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]amino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




RN 677726-78-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-79-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[4-[[[1-[[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-80-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[4-[[[1-[[[5R]-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[4-[[[1-[[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-82-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[4-[[[1-[[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 677726-87-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[4-[[[1-[[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




RN 677726-88-4 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-[[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677727-78-5 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[[[(5R)-3-[[3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-80-9 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[[[(5R)-3-[[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[methyl[3-[[1-[[[(5R)-3-[[4-methyl-2-thiazolyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677727-79-6 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[[[(5R)-3-[[3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-81-0 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[[[(5R)-3-[[3-fluoro-4-[(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-82-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[3-[1-[[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-83-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[3-[1-[[[(5R)-3-(3,4-dichlorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-90-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[3-[1-[[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-92-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[3-[1-[[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-95-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3,5-  
 difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]butyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-96-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3-  
 fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-  
 triazol-4-yl]ethoxy]carbonyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-  
 , (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-97-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3-  
 fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-  
 triazol-4-yl]ethoxy]carbonyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 677727-99-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(4-  
 [(dimethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-  
 triazol-4-yl]propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



Ngrazier 10671326Amend2

=> s 17

L11 1 L7

=> d ed abs ibib hitstr

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 09 Apr 2004  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention provides a family of bifunctional heterocyclic compds., e.g., I (A = C, C(=O), N (with proviso, that at least one A = C); B = O, NR2, S(O)r, C(=O), C(=S), C(=NR3); p = 0, 1; q = 0, 1; r = 0 - 2; R2 = H, S(O)R4, CHO, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR2R2 = 5 to 8-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R3 = H, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 7-membered heterocycle (containing one or more N, S, O); NR3R3 = 5 to (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NHCOR3, C(=O)NR3R3, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, etc.; D = D1, D2, D3, D4; E = di- or penta-substituted Ph, substituted 4-vinylphenyl; G = C1-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C,N,O,S; dashed line = single or double bond] or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as anti-infective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional heterocyclic compds., and methods of using such compds. as anti-infective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin derivative II was prepared from N-(desmethylerythromycin), via N-alkylation with HC.tpbond.CCH2CH2OTS, and cycloaddn. with azide III.

ACCESSION NUMBER: 2004:292029 HCAPLUS  
 DOCUMENT NUMBER: 140:321158  
 TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as anti-infective, antiproliferative, antiinflammatory and prokinetic agents  
 INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyale, Adegboyega K.; McConnell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.  
 PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 363 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030925
WO 2004029066	C1	20040513		
WO 2004029066	A3	20040826		


V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GU, GE,

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2005197334 A1 20050908 US 2003-671326 20030925  
 CA 2500158 AA 20040408 CA 2003-2500158 20030926  
 EP 1543017 A2 20050622 EP 2003-770506 20030926  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRIORITY APPLN. INFO.: US 2002-414207P P 20020926  
 WO 2003-448216P P 20030219  
 WO 2003-US30478 W 20030925

OTHER SOURCE(S): MARPAT 140:321158  
 IT 677726-15-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation and N-dealkylation of; preparation of bifunctional heterocyclic compds. for use as anti-infective, antiproliferative, antiinflammatory and prokinetic agents)  
 RN 677726-15-7 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A




IT 677726-17-9P 677726-31-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation and hydrolysis of; preparation of bifunctional heterocyclic compds. for use as anti-infective, antiproliferative, antiinflammatory and prokinetic agents)  
 RN 677726-17-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




PAGE 1-B

RN 677726-31-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[(5R)-3-[3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



IT 677726-16-0P 677726-18-0P 677726-26-0P  
 677726-27-1P 677726-28-2P 677726-29-3P  
 677726-30-6P 677726-33-9P 677726-34-0P  
 677726-35-1P 677726-36-2P 677726-46-4P  
 677726-47-5P 677726-48-6P 677726-49-7P  
 677726-50-0P 677726-51-1P 677726-52-2P  
 677726-53-3P 677726-54-4P 677726-55-5P  
 677726-57-7P 677726-58-8P 677726-60-2P  
 677726-62-4P 677726-63-5P 677726-65-7P  
 677726-66-8P 677726-68-0P 677726-70-4P  
 677726-72-6P 677726-73-7P 677726-74-8P  
 677726-75-9P 677726-76-0P 677726-77-1P  
 677726-78-3P 677726-79-3P 677726-80-6P  
 677726-81-7P 677726-82-8P 677726-83-9P  
 677726-84-0P 677726-89-5P 677726-90-8P  
 677727-77-4P 677727-78-5P 677727-79-6P  
 677727-80-9P 677727-81-0P 677727-82-1P  
 677727-83-2P 677727-84-3P 677727-85-4P  
 677727-86-5P 677727-87-6P 677727-88-7P  
 677727-89-8P 677727-90-1P 677727-91-2P  
 677727-92-3P 677727-93-4P 677727-94-5P  
 677727-95-6P 677727-98-9P 677727-99-0P  
 677728-00-6P 677728-01-7P 677728-02-8P

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A




RN 677726-18-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

677728-03-9P 677728-04-0P 677728-42-9P

678182-71-3DP, trans-cyclohexanol isomers


RI: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of bifunctional heterocyclic compds. for use as anti-infective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-16-8 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[3-[[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

677726-26-0 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-27-1 HCAPLUS


CN Erythromycin, N-[2-[[1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 677726-28-2 HCAPLUS  
 CN Erythromycin, N-[3-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 677726-29-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 677726-30-6 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[2-[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




PAGE 2-A



RN 677726-33-9 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[2-[1-[[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




PAGE 2-A



RN 677726-34-0 HCAPLUS  
 CN Erythromycin, N-[2-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




PAGE 2-A



RN 677726-36-2 HCAPLUS  
 CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-N-demethyl-N-[2-[1-[[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




PAGE 2-A



RN 677726-35-1 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[2-[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B



RN 677726-46-4 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B



RN 677726-47-5 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B




RN 677726-49-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[2-[1-[[[(5R)-3-[4-[[2-(acetoxy)ethyl]methylamino]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B



RN 677726-48-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 677726-50-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677726-51-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-52-2 HCAPLUS  
 CN Erythromycin, N,N-didemethyl-N-[2-[1-[[[5R]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 677726-53-3 HCAPLUS  
 CN Erythromycin, 3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-N-demethyl-N-[2-[1-[[[5R]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 677726-54-4 HCAPLUS  
 CN Erythromycin, 3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-N-demethyl-N-[2-[1-[[[5R]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 677726-55-5 HCAPLUS  
 CN 1-Oxa-6-azacyclotetradecan-15-one, 13-[[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[[[5R]-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B



RN 677726-57-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[5R]-3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B




RN 677726-60-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[5R]-3-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B



RN 677726-58-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[5R]-3-(4'-cyano-2-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[5R]-3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 677726-62-4 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[5R]-3-[4-(4-(dimethylamino)methyl)-1H-1,2,3-triazol-1-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-63-5 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[5R]-3-(4'-cyano-2-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[5R]-3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 1-A

PAGE 1-B




RN 677726-65-7 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[[[(5R)-3-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 1-A

PAGE 1-B




RN 677726-66-8 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[[[(5R)-3-[4-aminosulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-68-0 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[[2-[1-[[[(5R)-3-[4-aminosulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[[[(5R)-3-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-70-4 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[[2-[1-[[[(5R)-3-[4-aminosulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[[[(5R)-3-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-72-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[[4-  
 [[[(dimethylamino)methylene]amino]sulfonyl]phenyl]-2-oxo-5-  
 oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-  
 xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry unknown.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-73-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(3,4-  
 dichlorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-74-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(3,5-  
 difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-75-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[2-[1-[[[(5R)-3-(1,3-benzodioxol-  
 5-yl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]ethyl]methylamino]-3,4,6-trideoxy- $\beta$ -D-xylo-hexopyranosyl]oxy]-13-  
 [(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-  
 ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-  
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-76-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl(2-[[1-[[5R]-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A






PAGE 2-B



RN 677726-77-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl(4-[[1-[[5R]-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]amino]-β-D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A




RN 677726-78-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl(2-[[1-[[5R]-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]amino]-β-D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-79-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-80-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[4-[1-[[5R]-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-81-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B




RN 677726-82-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677726-83-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 677726-84-0 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]-1-propenyl)methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-89-5 HCAPLUS  
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-[[2-[[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 677726-90-8 HCAPLUS  
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-[[2-[[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 677727-78-5 HCAPLUS

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B



RN 677727-77-4 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[methyl[2-[[1-[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[methyl-3-[[1-[[[(5R)-3-  
 (4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]propyl]amino]-β-D-xylo-hexopyranosyl]oxy]-,  
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677727-79-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[3-[[1-[[[(5R)-3-(3-  
 fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,  
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-81-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[3-[[1-[[[(5R)-3-(3-  
 fluoro-4-[(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl)methyl]-  
 1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,  
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-80-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[3-[[1-[[[(5R)-3-(4-  
 (dimethylamino)-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-  
 triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,  
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-82-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[3-[[1-[[[(5R)-3-(3,5-  
 difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,  
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-83-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[[1-[[[(5R)-3-(3,4-dichlorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl)methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-84-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[[1-[[[(5R)-3-(2-fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-85-4 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[[1-[[[(5R)-3-(3-fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 677727-86-5 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[[1-[[[(5R)-3-(4-fluoro-3-methylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-87-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-(2-hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-88-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-(2-hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-89-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-(2-hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677727-90-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-(2-hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-91-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxyl]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxyl]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-92-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxyl]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxyl]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-93-4 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxyl]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(2-fluoro-4'-[[[4-quinolinylmethyl]amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxyl]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 677727-94-5 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxyl]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(3-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxyl]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 1-A




PAGE 1-B




RN 677727-95-6 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PAGE 1-A



PAGE 1-B




RN 677727-98-9 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-99-0 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677728-00-6 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[[(5R)-3-(3-chloro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677728-01-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[[1-[[5R]-3-cyclopentyl-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677728-02-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[methyl[2-[[1-[[5R]-2-oxo-3-[[4-(trifluoromethoxy)phenyl]-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677728-03-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[methyl[2-[[1-[[5R]-2-oxo-3-[[4-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677728-04-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[methyl[2-[[1-[[5R]-2-oxo-3-[[4-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B




RN 677729-42-9 HCAPLUS  
CN Erythromycin, N-demethyl-N-[2-[[[5R]-3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 678182-71-3 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[[5R]-3-(trans-4-hydroxycyclohexyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



Ngrazier 10671326Amend2

=> s 19

L12            41 L9

=> d ed abs ibib hitstr 1-41

L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 16 Sep 2005  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention provides macrocyclic azithromycin compds. I and II, wherein T is macrolide; R1 and R3 are independently H, alkyl, alkenyl, alkynyl, acyl ester, amide, thio-acyl, thio-ester, amine; R2 is H, alkoxy; D is single bond, alkyl, alkenyl, alkynyl, acyl, ester, amide, imine, sulfonyl, amine, thio-acyl, thio-amide; E is aromatic heterocycle, carbocycle, CO, CO, amide, imine; F is single bond, alkyl, alkenyl, alkynyl; G is aryl, heteroaryl, biaryl, bicyclic, tricyclic, acyl, were prepared as antibacterial, anti-proliferative, prokinetic, and antiinflammatory agents. Thus, III was prepared and used as antibacterial, anti-proliferative, and antiinflammatory agent.

ACCESSION NUMBER: 2005:1004760 HCAPLUS

DOCUMENT NUMBER: 143:306499

TITLE: Preparation of macrocyclic azithromycin compounds as antibacterial, anti-proliferative, and antiinflammatory agents  
 INVENTOR(S): Farmer, Jay J.; Bhattacharjee, Ashoke; Chan, Yi; Goldberg, Joel A.; Ippolito, Joseph A.; Kanyo, Zoltan F.; Lou, Rongliang; Oyler, Adeboyege K.; Sherer, Edward C.; Sutcliffe, Joyce A.; Wang, Daping; Wu, Yusheng; Du, Yanming

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 333 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085266	A2	20050915	WO 2005-US6082	20050225
V: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-548280P P 20040227  
 US 2004-575949P P 20040601

IT 864529-35-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of macrocyclic azithromycin compds. as antibacterial, anti-proliferative, and antiinflammatory agents)


L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 864529-35-1 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]methyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B

L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



PAGE 2-A

PAGE 2-B



IT 864529-37-7



RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of macrocyclic azithromycin compds. as antibacterial, anti-proliferative, and antiinflammatory agents)

RN 864529-37-7 HCAPLUS

CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[methylsulfonyl]oxy]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
ED Entered STN: 08 Sep 2005  
GI



AB Amidoxime and amidine oxazolidinones I [wherein X = certain O-containing five-membered heterocycle; W = CH<sub>2</sub>OH, CH<sub>2</sub>NHAc, etc.; Y<sub>1</sub> - Y<sub>3</sub> = CH, N, N(O) or CF; G = CH<sub>2</sub>, etc.; U = CH<sub>2</sub>, CF<sub>2</sub>, O, S, SO or SO<sub>2</sub>; R<sub>2</sub> = H or alkyl; V = N or C; Z = H, OH, alkoxy, etc., or pharmaceutically acceptable salts thereof] were prepared as antibacterial agents. For instance, II, which showed antibacterial activity with MIC values of 1-4 µg/mL against *S. aureus*, *S. pyogenes* and *S. pneumoniae*, was synthesized from Me bromoacetate and 2-amino-5-nitrophenol in eight steps. The invented compds. are potentially useful for the treatment of bacteria infectious diseases.

ACCESSION NUMBER: 2005:979647 HCAPLUS  
DOCUMENT NUMBER: 143:286413  
TITLE: Preparation of oxazolidinone compounds as antibacterial agents  
INVENTOR(S): Gordev, Mikhail Fedorovich; Jain, Rama; Josyula, Vasa  
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company LLC, USA  
SOURCE: PCT Int. Appl., 72 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082897	A1	20050909	WO 2005-1B102	20050117
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BU, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
ED Entered STN: 08 Jul 2005  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [A and B independently = Ph, pyridyl, pyrazinyl, etc.; M = (un)substituted alkyl, alkenyl, alkynyl; X = O, -N(O)-, -O-N-, etc.; L = (un)substituted alkyl, alkenyl, alkynyl; R<sub>1</sub> = halo, CF<sub>3</sub>, NO<sub>2</sub>, etc.; R<sub>2</sub> = CN, halo, CF<sub>3</sub>, etc.; R<sub>3</sub> = OR<sub>4</sub>, NR<sub>4</sub>R<sub>4</sub>, C(OR<sub>4</sub>), etc.; R<sub>4</sub> = H, alkyl, alkenyl, etc.; m = 0-4; n = 0-4] and their pharmaceutically acceptable salts, are prepared and disclosed as antiinflammatory agents. Thus, e.g., II was prepared by alkylation of amine III (preparation given) with 3-bromo-1,1,1-trifluoro-2-propanol. The activity of I was evaluated using surface binding studies and fluorescence polarization (no data). I should prove useful as antiinflammatory agents. Pharmaceutical compns. comprising I are disclosed.

ACCESSION NUMBER: 2005:588915 HCAPLUS  
DOCUMENT NUMBER: 143:97346  
TITLE: Preparation of halogenated biaryl oxazolidinones as antiinflammatory agents  
INVENTOR(S): Chen, Shili; Zhou, Jiacheng; Wu, Yunsheng; Wang, Deping; Salvino, Joseph M.; Oyeler, Adegboyega K.; Lou, Rongliang  
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA; Bhattacharjee, Ashoka; Chen, Yi  
SOURCE: PCT Int. Appl., 123 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061468	A1	20050707	WO 2004-US39988	20041201
WO 2005061468	C1	20050909		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BU, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
US 2005153971	A1	20050714	US 2004-1446	20041201
PRIORITY APPLN. INFO.: US 2003-530371P P 20031217				
US 2004-576267P P 20040602				


OTHER SOURCE(S): MARPAT 143:97346  
IT 856907-04-SP 856907-43-2P 856907-81-8P  
856907-85-2P 856907-86-3P 856907-87-4P  
856907-88-5P 856907-89-6P 856907-92-1P  
856907-97-6P 856907-98-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of halogenated biaryl oxazolidinones as antiinflammatory

L12 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
PRIORITY APPLN. INFO.: US 2004-540214P P 20040128  
IT 864073-59-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
RN 864073-59-6 HCAPLUS  
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-methyl-7-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]-, 3-(O-methylxime) (9CI) (CA INDEX NAME)  
Absolute stereochemistry.  
Double bond geometry unknown.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
RN 856907-04-5 HCAPLUS  
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.




RN 856907-43-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[(3-fluoro-2-hydroxypropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.



RN 856907-81-8 HCAPLUS


L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-methyl-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 856907-85-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 856907-88-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-[[5-(hydroxymethyl)-4-methyl-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-89-6 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[[4,5-bis(methoxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 856907-92-1 HCAPLUS  
 CN Acetamide, N-[[[1-[[[5R]-3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 856907-86-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-[[5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856907-87-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-[[4-(hydroxymethyl)-5-methyl-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 856907-97-6 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[[4-[(ethylthio)methyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 856907-98-7 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[[5-[(ethylthio)methyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[2-fluoro-4'-[[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 501939-95-3P 847490-64-6P 847490-65-7P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of halogenated biaryl oxazolidinones as antiinflammatory agents)  
 RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[(3-fluoro-4-iodophenyl)-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847490-64-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[(2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 30 Jun 2005  
 GI



AB Title compds. I [X = C, N; R1-1' = H, F; R2 = amino, alkoxy, triazolyl, etc.; R3-4 = H, alkyl, etc.; Het = heterocyclic ring, heteroarom. ring, etc.] are prepared. For instance, (R)-3-[4-[(2-methyltetrazol-5-yl)pyridin-5-yl]-3-fluorophenyl]-5-hydroxymethyl-oxazolidin-2-one (II) is prepared from 2-(2-methyltetrazol-5-yl)-5-bromopyridine and (R)-3-(4-tributylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinylmethanol (preparation given). II exhibits MIC50 = 0.5 µg/mL against MRSA and 0.25 µg/mL against VRE. I show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The amino acid or phosphate prodrugs of the invention show good water solubility. Further, the derivs. of the present invention may exert potent antibacterial activity vs. various human and animal pathogens, including Gram-pos. bacteria such as Staphylococci, Enterococci and Streptococci, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium.


ACCESSION NUMBER: 2005:564663 HCAPLUS  
 DOCUMENT NUMBER: 143:97343  
 TITLE: Preparation of oxazolidinone broad-spectrum antibiotics  
 INVENTOR(S): Rhee, Jae Keol; Im, Yeon Bin; Cho, Chong Hwang; Choi, Sung Hak; Lee, Tae Ho  
 PATENT ASSIGNEE(S): Dong-A Pharm.Co., Ltd., S. Korea  
 SOURCE: PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058886	A1	20050630	WO 2004-KR3327	20041217
W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.:  
 KR 2003-93342 A 20031218  
 KR 2004-58809 A 20040727


OTHER SOURCE(S): MARPAT 143:97343  
 IT 700370-32-7P 831201-38-8P 856866-76-7P  
 856866-77-8P 856867-06-8P 856867-08-8P

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 847490-65-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[(4'-(chloromethyl)-2-fluoro[1,1'-biphenyl]-4-yl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RI: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of oxazolidinone broad-spectrum antibiotics effective against MRSA and VRE)  
 RN 700370-32-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[(3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-38-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[(3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 856866-76-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[(3-fluoro-4-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridinyl]phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 856866-77-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856867-06-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[4-(hydroxymethyl)-2-thiazolyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of oxazolidinone broad-spectrum antibiotics effective against MRSA and VRE)


RN 856867-07-7 HCAPLUS  
 CN Glycine, [2-[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4-thiazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 856867-08-8 HCAPLUS  
 CN Glycine, [2-[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4-thiazolyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 856867-07-7  
 CHF C24 H21 F N6 O4 S

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CHF C2 H F3 O2



IT 856867-07-7

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 17 Jun 2005  
 GI



II

AB The present invention provides agents having antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel substituted piperidino phenylloxazolidinone derivs. (shown as I) variables defined below: e.g. (S)-N-[[3-[4-(4-cyanomethyl-4-hydroxypiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide (shown as II)), processes for making compds. as well as antimicrobial compns. containing said derivs. as active ingredients and methods of treating bacterial infections with the said derivs. MIC (μg/mL) and/or ED50 (mg/kg) values are tabulated for 5 types of bacteria. For I: m = 0-1 and n = 1-3; X = -CN, -OH, or halogen; Y = H (with the proviso that when Y is H, X is OH, F or CN), (un)substituted C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heterocyclylamino, heterocyclylcarbonyl, cyano, halogen, (un)substituted amino, (un)substituted hydrazino; or X and Y together form a 3-membered carbocyclic ring or heterocyclic ring containing a hetero atom = O or S or X and Y together form an (un)substituted, (un)saturated 3 to 7 membered heterocyclic ring having 1-4 hetero atoms = N, O, S or includes the S atom of groups like sulfinyl or sulfonyl as a part of heterocyclic ring or X and Y together form O; A, B = H, C1-C6 alkyl, or halogens; R2, R3 = H or halogen. R4 = C1-C6 alkylsulfonyloxy, alkylsulfonyloxycetamido, (un)substituted aminosulfonyloxy, alkylsulfonyloxy, arylsulfonyloxy, (un)substituted amino, azido, aminonitrilo, isocyanato, formamido, N-hydroxyformamido, substituted C1-C6 alkanoyloxy, (un)substituted C1-C6 alkylamido, (un)substituted C1-C6 alkylthiocarbonylamido, C1-C6 alkylsulfonylamido; substituted arylsulfonylamido, (un)substituted alkylcarbamato, (un)substituted ureido, (un)substituted five to six membered heterocyclyl ring, (un)substituted five to six membered heteroaryl ring, (un)substituted heteroaryloxy, (un)substituted heteroarylamino, or mercapto substituted by C1-C6 alkyl group; addnl. details including provisos are given in the claims. Methods of preparation are claimed and .apprx.180 example preps. are included. For example, S1 & II was prepared by reacting (S)-N-[[3-[4-(1-oxa-6-azaspiro[2.5]octan-6-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide with KCN in MeOH/DMF (1:5) at 25° for 14 h.

ACCESSION NUMBER: 2005:523447 HCAPLUS  
 DOCUMENT NUMBER: 143:59964  
 TITLE: Preparation of 3-(4-piperidinophenyl)oxazolidinones


L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 having antibacterial activity with improved in vivo efficacy  
 INVENTOR(S): Deshpande, Prasad Keshav; Sindkhedkar, Milind  
 Dattatraya; Phansalkar, Mahesh Shriram; Yeole, Ravindra Dattatraya; Gupte, Shrikant Vinayak; Chugh, Yati; Shetty, Nitin; Bhagwat, Sachin Subhash; De Souza, Noel John; Patel, Mahesh Vithalbhai  
 PATENT ASSIGNER(S): India  
 SOURCE: PCT Int. Appl., 167 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054234	A2	20050616	WO 2004-IN276	20040908
WO 2005054234	A3	20050929		


V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GB, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005143421 A1 20050630 US 2004-935708 20040907  
 PRIORITY APPLN. INFO.: IN 2003-MU924 A 20030908  
 OTHER SOURCE(S): MARPAT 143:59964  
 IT 853797-09-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate: preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)  
 RN 853797-09-8 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[5(R)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 853797-08-7 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[5(S)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-10-1 HCAPLUS  
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[[5(S)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853797-11-2 HCAPLUS  
 CN 1H-1,2,3-Triazole-5-carboxamide, 1-[[5(S)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 IT 853797-04-3P, (S)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-4-carboethoxy-1,2,3-triazole  
 853797-06-5P, (S)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-4-aminocarbonyl-1,2,3-triazole  
 853797-08-7P, (S)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-4-cyano-1,2,3-triazole  
 853797-10-1P, (S)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-5-carboethoxy-1,2,3-triazole  
 853797-11-2P, (S)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-5-aminocarbonyl-1,2,3-triazole  
 853797-12-3P, (S)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-5-cyano-1,2,3-triazole  
 853797-45-2P, (R)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-4-cyano-1,2,3-triazole  
 853797-46-3P, (R)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-5-carboethoxy-1,2,3-triazole  
 853797-47-4P, (R)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-5-aminocarbonyl-1,2,3-triazole  
 853797-48-5P, (R)-1-[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-5-cyano-1,2,3-triazole  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate: preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)  
 RN 853797-04-3 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[5(S)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853797-06-5 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[5(S)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 853797-12-3 HCAPLUS  
 CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[[5(S)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-45-2 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[5(R)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853797-46-3 HCAPLUS  
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[[5(R)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 853797-47-4 HCAPLUS  
 CN 1H-1,2,3-Triazole-5-carboxamide, 1-[[[(5R)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-48-5 HCAPLUS  
 CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[[[(5R)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




IT 853797-07-6, (R)-1-[[[3-[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidin-5-yl]methyl]-4-carboethoxy-1,2,3-triazole  
 RI: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)  
 RN 853797-07-6 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[[(5R)-3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-,

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 01 Jun 2005  
 AB A new series of N-linked 5-triazolylmethyl oxazolidinones with varying substitution at the piperazine nitrogen 4-position were synthesized and tested against a panel of Gram-pos. and Gram-neg. bacteria including clin. isolates. Most of the compds. showed excellent antibacterial activity against susceptible and resistant Gram-pos. organisms. One of the compds. showed enhanced antibacterial activity against Moraxella catarrhalis.  
 ACCESSION NUMBER: 2005:465012 HCAPLUS  
 DOCUMENT NUMBER: 143:149749  
 TITLE: Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones  
 AUTHOR(S): Phillips, Oludotun A.; Udo, Edet E.; Ali, Ahmed A. M.; Samuel, Santhosh M.  
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Safat, 13110, Kuwait  
 SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(12), 4113-4123  
 CODEN: BMCECP; ISSN: 0968-0896  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 371195-29-8P  
 RI: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones)  
 RN 371195-29-8 HCAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 859445-41-3P 859445-42-4P 859445-43-5P  
 859445-44-6P 859445-45-7P 859445-46-8P  
 859445-47-9P 859445-48-0P 859445-49-1P  
 859445-50-2P 859445-51-3P 859445-52-4P  
 859445-53-5P 859445-54-6P 859445-55-7P  
 859445-56-8P

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RI: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones)  
 RN 859445-41-3 HCAPLUS  
 CN 1-Piperazinecarboxaldehyde, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-42-4 HCAPLUS  
 CN Piperazine, 1-acetyl-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-43-5 HCAPLUS  
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 859445-44-6 HCAPLUS  
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(trichloroacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-45-7 HCAPLUS  
 CN Piperazine, 1-(dichloroacetyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-48-0 HCAPLUS  
 CN Piperazine, 1-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-49-1 HCAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-46-8 HCAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, S-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-47-9 HCAPLUS  
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-50-4 HCAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, S-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-51-5 HCAPLUS  
 CN Piperazine, 1-(1,2-dioxopropyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-52-6 HCAPLUS  
 CN Piperazine, 1-(2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl)-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-53-7 HCAPLUS  
 CN Piperazine, 1-(cyclopentylcarbonyl)-4-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 859445-55-9 HCAPLUS  
 CN Piperazine, 1-benzoyl-4-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-56-0 HCAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 859445-40-2P  
 RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (synthesis and antibacterial activity of new N-linked 5-triazolylmethyl


L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-54-8 HCAPLUS  
 CN Piperazine, 1-(cyclohexylcarbonyl)-4-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 859445-40-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 371195-30-1  
 CMF C16 H19 F N6 O2

Absolute stereochemistry.



CH 2

CRN 76-05-1  
 CMF C2 H F3 O2




REFERENCE COUNT:

28

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 13 May 2005  
 GI




AB The invention relates to a preparation of novel oxazolidinone derivs. of formula I (R is H, amide, aldehyde, or nitrile, etc.; each X is independently N or CH), useful as antibacterial agents. For instance, oxazolidinone derivative II [MIC (μg/mL): str. pyogenes 77A - 0.4, s. aureus 285 - 0.8, MRSA 2 - 1.6; LD50 >5000 mg/kg] was prepared via 1,3-dipolar cycloaddn. of vinyl acetate to (azidomethyl)oxazolidinone derivative III with a yield of 74%.

ACCESSION NUMBER: 2005:409511 HCAPLUS  
 DOCUMENT NUMBER: 1421463731  
 TITLE: A preparation of novel oxazolidinone derivatives, useful as antibacterial agents  
 INVENTOR(S): Kang, Jae-Hoon; Park, Chun-Ho; Rwon, Jin-Sun  
 PATENT ASSIGNER(S): Il-Dong Pharm. Co., Ltd., S. Korea  
 SOURCE: PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042523	A1	20050512	WO 2004-KR2805	20041103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,				

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Double bond geometry unknown.




RN 851529-83-4 HCAPLUS  
 CN 1H-Pyrazole-3-carbonitrile, 1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-97-0 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-98-1 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-, 4-oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry unknown.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, HL, HR, NE, SN, TD, TG

PRIORITY APPL. INFO.: KR 2003-77372 A 20031103  
 KR 2004-62328 A 20041014


OTHER SOURCE(S): MARPAT 142:463731  
 IT 851529-76-5P 851529-81-2P 851529-82-3P  
 851529-83-4P 851529-97-0P 851529-98-1P  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of novel oxazolidinone derivs. useful as antibacterial agents)  
 RN 851529-76-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-81-2 HCAPLUS  
 CN 1H-Pyrazole-3-carboxaldehyde, 1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851529-82-3 HCAPLUS  
 CN 1H-Pyrazole-3-carboxaldehyde, 1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-, 3-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 851530-02-4P  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of novel oxazolidinone derivs. useful as antibacterial agents)


RN 851530-02-4 HCAPLUS  
 CN 1H-Pyrazole-4-carbonitrile, 1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851529-77-6P 851529-96-9P 851530-00-2P  
 851530-01-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of novel oxazolidinone derivs. useful as antibacterial agents)  
 RN 851529-77-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 851529-96-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-{4-(diethoxymethyl)-1H-1,2,3-triazol-1-yl}-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851530-00-2 HCAPLUS  
 CN 1H-Pyrazole-4-carboxylic acid, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851530-01-3 HCAPLUS  
 CN 1H-Pyrazole-4-carboxamide, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 851529-86-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(2H-tetrazol-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-87-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 851529-88-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 851529-78-7P 851529-85-6P 851529-86-7P  
 851529-87-8P 851529-88-9P 851529-89-0P  
 851529-90-3P 851529-91-4P 851529-92-5P  
 851529-93-6P 851529-94-7P 851529-95-8P  
 851529-99-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-78-7 HCAPLUS

CN Carbamic acid, [2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl] (phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851529-85-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 851529-89-0 HCAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 851529-90-3 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851529-76-5  
 CMF C16 H18 F N5 O2

Absolute stereochemistry.



L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CM 2

CRN 7664-93-9  
CHF H2 O4 5RN 851529-91-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851529-77-6  
CHF C16 H14 F N5 O2

Absolute stereochemistry.




CM 2

CRN 7664-93-9  
CHF H2 O4 5RN 851529-92-5 HCAPLUS  
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1


L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 77-92-9  
CHF C6 H8 O7RN 851529-94-7 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 851529-77-6  
CHF C16 H14 F N5 O2

Absolute stereochemistry.



CM 2

CRN 77-92-9  
CHF C6 H8 O7RN 851529-95-9 HCAPLUS  
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 851529-83-4  
CHF C17 H13 F N6 O2

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 851529-83-4  
CHF C17 H13 F N6 O2

Absolute stereochemistry.




CM 2

CRN 7664-93-9  
CHF H2 O4 5RN 851529-93-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 851529-76-5  
CHF C16 H18 F N5 O2

Absolute stereochemistry.




CM 2


L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 77-92-9  
CHF C6 H8 O7

CM 2

CRN 77-92-9  
CHF C6 H8 O7RN 851529-99-2 HCAPLUS  
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 851529-80-1P 851529-84-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of novel oxazolidinone derivs. useful as antibacterial agents)  
 RN 851529-80-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-(4-amino-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 851529-84-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-azido-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 04 Mar 2005  
 GI



AB Title compds. represented by the formula I [wherein A = isoxazolin-3,5-diyl, 2-oxazolinone-3,5-diyl, 2-furanone-3,5-diyl, 5-isoxazolinone-2,4-diyl; X = N or C; Z = oxy-isoxazolyl, (oxy)-1,2,3-triazolyl, aminocarbonylmethyl, etc.; R2-R5 = independently H, Cl, F, Me, NH2, or OH; L, Y = independently H, OH, F, O, NOH, NOalkyl; m, n, p = independently 0 or 1; and pharmaceutically acceptable salts thereof] were prepared as antimicrobial agents. For example, II was given in a multi-step synthesis starting from the reaction of 1,2,3,6-tetrahydropyridine with 3,4-difluoronitrobenzene. I were tested for inhibition against SAUA 9213, SPNE 9912, HINF 30063 and MC 30603 with MIC values of 0.25-64 µg/mL. Thus, I and their pharmaceutical compns. are useful as antibacterial agents for the treatment of a gram-neg. microbial infection.

ACCESSION NUMBER: 2005:182660 HCAPLUS  
 DOCUMENT NUMBER: 142:280197  
 TITLE: Preparation of aryloxazolidinone derivatives as antimicrobial agents  
 INVENTOR(S): Gordeev, Mikhail; Wang, Qiang  
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA  
 SOURCE: PCT Int. Appl., 107 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019214	A1	20050303	WO 2004-1B2669	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				


L12 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN: BW, GH, GM, KE, LS, MW, NZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005065187 A1 20050324 US 2004-924752 20040824  
 PRIORITY APPL. INFO.: US 2003-497531P P 20030825  
 OTHER SOURCE(S): MARPAT 142:280197

IT 847256-81-9P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of aryloxazolidinone derivs. as antimicrobial agents)  
 RN 847256-81-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(3S,4R)-3,4-dihydroxy-1-piperidinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 847256-82-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aryloxazolidinone derivs. as antimicrobial agents)  
 RN 847256-82-0 HCAPLUS  
 CN 4-Piperidinone, 1-[2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-hydroxy-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 847257-18-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of aryloxazolidinone derivs. as antimicrobial agents)  
 RN 847257-18-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(3S,4R)-3,4-dihydroxy-1-piperidinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 04 Mar 2005  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [A and B independently = Ph, pyridyl, pyrazinyl, pyrimidinyl, or pyridazinyl; R1 and R2 = independently = halo, CF3, CN, NO2, NR42, COR4, etc.; R3 = OR4, NR42, COR4, CO2R4, CSR4, etc.; R4 independently = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -aryl, etc.; M = (un)substituted, (un)saturated carbocycle or aryl heterocycle containing one or more heteroatoms chosen from N, O, and S; L = X, LI, LIX, XL2, LIXL2, XLXL2, LIXLX2, X2, LIX2, XL2, LIXL2 wherein X independently = O, NR4, NO, N(OR4), NR4R4, etc., and L1 and L2 are independently = (un)substituted-alkyl, -alkenyl, -alkynyl; a = 0-4; n = 0-4], and their pharmaceutically acceptable salts, are prepared. Thus, e.g., II was prepared by conversion of TBDPS protected 1-bromo-4-(2-hydroxyethyl)benzene to the arylboronic acid which is coupled with N-(3-(3-fluoro-4-iodophenyl)-2-oxo-oxazolidin-5-ylmethyl)acetamide followed by desilylation, mesylation, and substitution with imidazole. I are disclosed as potential anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents (no data). More particularly, the invention relates to a family of compds. having both a biaryl moiety and at least one heterocyclic moiety that are useful as such agents.


ACCESSION NUMBER: 2005:182657 HCAPLUS  
 DOCUMENT NUMBER: 142:280195  
 TITLE: Preparation of biaryl heterocyclic compounds and methods of making and using the same in pharmaceutical applications  
 INVENTOR(S): Zhou, Jiaohong; Bhattacharjee, Ashoke; Chen, Shili; Chen, Yi; Farmer, Jay J.; Goldberg, Joel A.; Hanselmann, Roger; Lou, Rongliang; Orbin, Alia; Oyler, Adegboyega K.; Salvino, Joseph M.; Springer, Dane M.; Tran, Jennifer; Wang, Deping; Wu, Yusheng  
 PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 259 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019211	A2	20050303	WO 2004-US17101	20040602
WI:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

L12 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 US 2005203147 A1 20050915 US 2005-118808 20050429  
 PRIORITY APPL. INFO.: US 2003-475430P P 20030603  
 US 2003-475453P P 20030603  
 US 2003-490855P P 20030729  
 US 2003-529731P P 20031215  
 US 2003-531584P P 20031219  
 US 2004-859476 A1 20040602


OTHER SOURCE(S): MARPAT 142:280195  
 IT 847489-40-1P 847490-40-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of biaryl heterocyclic compound as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents)  
 RN 847489-40-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(1H-imidazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847490-40-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(1H-imidazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl


L12 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 IT 501939-95-3P 847490-64-6P 847490-65-7P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of biaryl heterocyclic compound as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents)  
 RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847490-64-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847490-65-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-(chloromethyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)





L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
 ED Entered STN: 21 Jan 2005  
 GI



AB New oxazolidinones having a cyclopropyl moiety (I) [R1, R2 = independently H, NR5R6, CR7R8R9, C(R10R11)2, CH2NR14, C(O)R13, C(=NOH)H, C(=NOR13)H, C(=NR13)R13, C(=NOR33)R, C(O)N(R13)2, C(O)N(R13)2, C(=NOH)N(R13)2, NHC(=X1)N(R13)2, C(=NH)R7, N(R13)C(=X1)N(R13)2, CO2R13, SO2R14, N(R13)SO2R14, N(R13)COR14, cyano-C1-6 alkyl, cyano, CH2C(R)2, etc.; A = C, CH, N --- represents an optional bond; ring A = aryl, heteroaryl, heterocyclyl; R5 = H, C1-6 alkyl; R3 = (un)substituted aromatic heterocyclic group containing at least one nitrogen in the ring which is attached through a bond on any N; R4, R6 = H, halogen, C1-6 alkoxy, C1-6 alkyl; r, s = 1-3, provided that r+s ≤ 4; R5, R6 = H, each (un)substituted C1-6 alkyl, C1-6 acyl, or C1-6 alkylsulfonyl, etc.; R7 = H, halo, cyano, CO2R, CON(R)2, CHO, CH2NHAc, C(=NOR), OH, C1-6 alkoxy, C1-6 alkyl, alkenyl, (CH2)nNH2, etc.; R8, R9 = H, cyano, each (un)substituted C1-6 alkyl or Ph; X1 = O, S, NR13, NCN, NCO2R16, or NSO2R14; R13 = H, C1-6 alkyl, C6-10 aryl, NR5R6, SR8, S(O)R8, S(O)2R8, cyano, OH, C1-6 alkoxy, carbonyl, CO2H, etc.; R14 = amino, C1-6 alkyl, C1-6 haloalkyl, (un)substituted Ph, etc.; R15 = C1-6 alkyl or (un)substituted benzyl; m, n, p, q = 0, 1], enantiomers, diastereomers, or pharmaceutically acceptable salts, hydrates, or prodrugs thereof are prepared. These compounds are effective as antibacterial agents against aerobic and anaerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides sp., Clostridia sp., as well as acid-fast organisms such as Mycobacterium tuberculosis and other mycobacterial species. They are coadministered with vitamin B2, vitamin B4, vitamin B12, or folic acid to prevent or treat oxazolidinone-associated side effects such as normocytic anemia, peripheral sensory neuropathy, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis,

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 hypo-regenerative anemia, megaloblastic anemia and seborrheic dermatitis. Thus, (R)-5-azidomethyl-3-[4-[[[1a,5a,6a]-6-(tert-butoxycarbonylamino)-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]oxazolidin-2-one (370 mg) and 2,5-norbornadiene (891 mg) in dioxane (65 mL) was heated at 70° for 6 h, and then concd. in vacuo. A suspension of the residue in diethylene glycol di-Me ether (18.5 mL) was heated at 140° for 10 min to give 1-[[[5R]-3-[[[1a,5a,6a]-6-(tert-butoxycarbonylamino)-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole which was treated with 12 N HCl/MeOH at room temp. for 10.5 h to give, after workup, compd. (II) (X = H). II (X = F) showed min. inhibitory concn. of 0.25, 0.25, 1, and 1 µg/mL against methicillin-resistant Staphylococcus aureus, penicillin- and quinolone-resistant S. pneumoniae, S. pyogenes IID692, vancomycin- and quinolone-resistant Enterococcus faecium, and Moraxella catarrhalis ATCC25238, resp.


ACCESSION NUMBER: 2005:58200 HCAPLUS  
 DOCUMENT NUMBER: 142:155957  
 TITLE: Preparation of 3-aryloxazolidin-2-one derivatives as antibiotics  
 INVENTOR(S): Hammond, Milton L.; Fukuda, Yasumichi  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.  
 SOURCE: PCT Int. Appl., 43 pp.  
 CODEN: FIMX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005422	A1	20050120	WO 2004-US20738	20040629
W: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.: US 2003-483901P P 20030702  
 US 2004-546985P P 20040224


OTHER SOURCE(S): MARPAT 142:155957  
 IT 828915-21-SP 828915-22-SP 828915-23-7P  
 828915-24-SP  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (Preparation of aryloxazolidin-2-one deriva. as antibacterial agents)  
 RN 828915-21-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[[[1,1-dimethylethyl]diphenylsilyl]oxy]methyl]bi-cyclo[3.1.0]hex-2-en-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 Absolute stereochemistry.




RN 828915-22-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[[[1,1-dimethylethyl]diphenylsilyl]oxy]methyl]bi-cyclo[3.1.0]hex-2-en-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-23-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-(hydroxymethyl)bi-cyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 828915-24-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(hydroxymethyl)bi-cyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




IT 828252-93-3P 828252-94-4P 828915-25-9P  
 828915-26-OP  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Preparation of aryloxazolidin-2-one deriva. as antibacterial agents)  
 RN 828252-93-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[[[1a,5a,6a]-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828252-94-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[[[1a,5a,6a]-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 828915-25-9 HCAPLUS


L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Bicyclo[3.1.0]hex-2-ene-6-carbonitrile, 3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-26-0 HCAPLUS  
 CN Bicyclo[3.1.0]hex-2-ene-6-carbonitrile, 3-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-70-4P 501939-95-3P 828252-99-9P  
 828253-00-5P 828915-27-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of aryloxazolidin-2-one derivs. as antibacterial agents)  
 RN 501939-70-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 828253-00-5 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6a)-3-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 828915-27-1 HCAPLUS  
 CN Bicyclo[3.1.0]hex-2-ene-6-carboxaldehyde, 3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828252-99-9 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6a)-3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 21 Jan 2005  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Oxazolidinones I and II [wherein R1, R2 = independently H, NH2, CH3 and derivs., CHO and derivs., CONH2 and derivs., SO2H and derivs., (un)substituted heterocyclyl, etc.; Y, Z = (un)substituted arylene, heteroarylene; R1a = defined as R1 less H, V = O, R, OH, or halor A = C or N with provisos; R<sub>x</sub> = H, alkyl; R3 = NHC(=O)H and derivs., NHC(=O)H and derivs., (un)substituted NH-heteroaryl, etc.; B = (CH2)<sub>n</sub>; n = 0-1; and their enantiomers, diastereomers, or their pharmaceutically acceptable salts, esters, hydrates or prodrugs] are effective against aerobic and anaerobic pathogens such as multi-resistant Staphylococci, Streptococci and Enterococci, Bacteroides, Clostridia, as well as acid-fast organisms such as Mycobacterium tuberculosis, and other mycobacterial species. Thus, reacting N-[(5S)-3-(3-fluoro-4-iodophenyl)-2-oxoxazolidin-5-yl]methyl]acetamide with bis(pinacolato)diboron, and Pd-coupling with 5-bromo-2-(1-cyanocyclopropan-1-yl)pyridine gave oxazolidinone III. The prepared oxazolidinones were tested for antibacterial activity against a variety of strains, such as Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecium. III inhibited Staphylococcus aureus Smith in vitro with a min. inhibitory concentration of 0.06 µg/ml.


ACCESSION NUMBER: 2005:58198 HCAPLUS  
 DOCUMENT NUMBER: 142:155938  
 TITLE: Preparation of cyclopropyl group substituted oxazolidinones as antibiotics  
 INVENTOR(S): Fukuda, Yasumichi  
 PATENT ASSIGNER(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.  
 SOURCE: PCT Int. Appl., 85 pp.  
 DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English  
 PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005420	A1	20050120	WO 2004-US20737	20040629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BF, BH, BM, BN, BR, BS, BT, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
SI, SK, TR, BF, BJ, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2003-483904P P 20030702 US 2004-546980P P 20040224				

OTHER SOURCE(S): MARPAT 142:155938  
 IT 827627-91-8P 827627-99-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (antibacterial agent; preparation of cyclopropyl-oxazolidinones as


L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
antibiotics)  
RN 827627-75-8 HCAPLUS  
CN Carbamic acid, [(1*a*,5*a*,6*a*)-3-[5-[4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827627-91-8 HCAPLUS  
CN Carbamic acid, [(1*a*,5*a*,6*a*)-3-[5-[2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827627-98-5 HCAPLUS  
CN Carbamic acid, [1-[5-[2-fluoro-4-[(5*R*)-5-[(4-methyl-1*H*-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827627-77-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[6-[(1-aminocyclopropyl)-3-pyridinyl]phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-, (5*R*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827627-78-1 HCAPLUS  
CN Cyclopropanecarbonitrile, 1-[5-[4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 827627-76-9P 827627-77-0P 827627-78-1P  
827627-79-2P 827627-82-9P 827627-97-4P  
827627-99-6P 827628-11-5P 827628-12-6P  
827628-13-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)

RN 827627-76-9 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[6-[(1-aminocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-, (5*R*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827627-79-2 HCAPLUS  
CN Cyclopropanecarbonitrile, 1-[5-[2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827627-92-9 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[6-[(1*a*,5*a*,6*a*)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-, (5*R*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827627-97-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6a)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827627-99-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827628-13-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3,5-difluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-70-4P 501939-95-3P 827628-21-7P  
 827628-30-8P 827628-34-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (Intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)  
 RN 501939-70-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(4-iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827628-11-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827628-12-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-5-fluoro-3-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-(3-fluoro-4-iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827628-21-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827628-30-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)




L12 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827015-45-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[[4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 20 Jan 2005  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Oxazolidinones I and II [wherein R1 = H, CH3 and derivs., CHO and derivs., CN, (un)substituted heterocyclyl; Y = NH and derivs., O, CN, S, SO, SO2; A, B = (un)substituted arylene, heteroarylene, heterocyclylene, etc.; D = (CH2)n; n = 0-1; R3 = NH2 and derivs., aryl, NRC(:X2)H and derivs.; R = H, alkyl; X2 = O, S, NH, etc.; Z = substituted aromatic heterocyclic group containing 1 to 4 nitrogens and at least one double bond; and their enantiomers, diastereomers, or their pharmaceutically acceptable salts, esters, hydrates or prodrugs] are effective against aerobic and anaerobic pathogens such as multi-resistant Staphylococci, Streptococci and Enterococci, Bacteroides, Clostridia, as well as acid-fast organisms such as Mycobacterium tuberculosis, and other mycobacterial species. Thus, II-HCl was prepared by reacting N-[5(S)-3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (preparation given) with bis(pinacolato)diboron, Pd-coupling with 5-bromo-2-[(1a,5a,6b)-3-tert-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridine (preparation given), and BOC-deprotection. The prepared oxazolidinones were tested for antibacterial activity against a variety of strains, such as Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecium. II inhibited Staphylococcus aureus Smith in vitro with a min. inhibitory concentration of 0.125 µg/mL.


ACCESSION NUMBER: 2005:55212 HCAPLUS  
 DOCUMENT NUMBER: 142:155937  
 TITLE: Preparation of cyclopropyl group substituted oxazolidinones as antibiotics  
 INVENTOR(S): Fukuda, Yasumichi  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.  
 SOURCE: PCT Int. Appl., 170 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005398	A2	20050120	WO 2004-US20734	20040629
WO 2005005398	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, GU, HD, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BU, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005038092	A1	20050217	US 2004-878637	20040629

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 PRIORITY APPLN. INFO.: US 2003-483904P P 20030702  
 US 2004-546984P P 20040224

OTHER SOURCE(S): MARPAT 142:155937  
 IT 831201-06-0P 831201-08-2P 831201-09-3P  
 831201-14-0P 831201-16-2P 831201-28-6P  
 831201-34-4P 831201-40-2P 831201-52-6P  
 831201-54-8P 831201-56-0P 831201-64-0P  
 831201-66-6P 831201-68-8P 831201-92-4P  
 831201-96-8P 831201-98-0P 831202-08-5P  
 831202-10-9P 831202-12-1P 831202-28-9P  
 831202-30-3P 831202-46-1P 831202-54-1P  
 831202-55-2P 831202-56-3P 831202-58-5P  
 831202-61-0P 831202-63-4P 831202-67-6P  
 831202-69-8P 831202-71-2P 831202-73-4P  
 831202-74-5P 831202-75-6P 831202-78-9P  
 831222-08-3P 831222-09-4P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)  
 RN 831201-06-0 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[3-fluoro-4'-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-08-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-09-3 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[[5-[(4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-14-0 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3-difluoro-4'-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 831201-16-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-((5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl)-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-28-6 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 831201-52-6 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2,6-difluoro-4-((5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl)-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-54-8 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2'-fluoro-4'-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1a,5a,6b) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 831201-34-4 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-40-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3,5-trifluoro-4'-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1a,5a,6b) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 831201-56-0 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-64-0 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-, (1a,5a,6b) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-86-6 HCAPLUS  
 CN Carbamic acid, [1-[[[(1a,5a,6b)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-OBu-t


RN 831201-88-8 HCAPLUS

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-98-0 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(acetyloxy)acetyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-08-5 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-(2-aminoethyl)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-92-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-96-8 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[[(1,1-dimethylethoxy)carbonyl]amino]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-10-9 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5R)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-12-1 HCAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-[(1a,5a,6b)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 831202-28-9 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-30-3 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 831202-55-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-(bromosuccinyl)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-56-3 HCAPLUS  
 CN Carbanic acid, [(1a,3B,5a,6B)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-46-1 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-54-1 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


Absolute stereochemistry.



RN 831202-58-5 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6B)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


-OBu-t

RN 831202-61-0 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6B)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—OBu-t

RN 831202-65-4 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—OBu-t

RN 831202-71-2 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-73-4 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B

—OBu-t

RN 831202-67-6 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OBu-t

RN 831202-69-8 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-fluoro-, 1,1-dimethylethyl ester, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



RN 831202-74-5 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-75-6 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-78-9 HCAPLUS  
 CN Carbamic acid, [(1a,3b,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831222-08-3 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

831202-17-0P 831202-18-7P 831202-19-8P  
 831202-20-1P 831202-21-2P 831202-22-3P  
 831202-23-4P 831202-24-5P 831202-27-8P  
 831202-29-0P 831202-31-4P 831202-32-5P  
 831202-33-6P 831202-34-7P 831202-37-0P  
 831202-42-7P 831202-45-0P 831202-53-0P  
 831202-57-4P 831202-59-6P 831202-63-2P  
 831202-64-3P 831202-66-5P 831202-81-4P  
 831203-07-7P 831221-99-9P 831222-02-7P  
 831222-03-8P 831222-06-1P 831222-07-2P  
 831222-10-7P 831222-11-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (antibacterial agent; prepn. of cyclopropyl-oxazolidinones as antibiotics)

RN 831201-07-1 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[3-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831201-13-9 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 831222-09-4 HCAPLUS  
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 831201-07-1P 831201-13-9P 831201-15-1P  
 831201-17-3P 831201-29-7P 831201-31-1P  
 831201-35-8P 831201-37-7P 831201-38-8P  
 831201-39-9P 831201-41-3P 831201-50-4P  
 831201-51-5P 831201-53-7P 831201-55-9P  
 831201-57-1P 831201-61-7P 831201-65-1P  
 831201-84-4P 831201-85-5P 831201-87-7P  
 831201-89-9P 831201-90-2P 831201-91-3P  
 831201-93-5P 831201-94-6P 831201-95-7P  
 831201-97-9P 831201-99-1P 831202-04-1P  
 831202-05-2P 831202-06-3P 831202-07-4P  
 831202-09-6P 831202-11-0P 831202-13-2P  
 831202-14-3P 831202-15-4P 831202-16-5P


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-15-1 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3'-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831201-17-3 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-29-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6b)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-31-1 HCAPLUS  
 CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-38-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-39-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-35-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6b)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-37-7 HCAPLUS  
 CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-41-3 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,5-trifluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831201-50-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3,6'-trifluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-51-5 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,6'-trifluoro-4'-{(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl}[1,1'-biphenyl]-4-yl]-, monohydrochloride, (1a,5a,6b) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831201-53-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-{2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl}-2-pyridinyl]-, monohydrochloride, (1a,5a,6b) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 831201-61-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-{2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl}-2-pyridinyl]-, (1a,5a,6b) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-65-1 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-{2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl}-2-pyridinyl]-, 3,3-dioxide, (1a,5a,6b) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-55-9 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2'-fluoro-4'-{(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl}[1,1'-biphenyl]-4-yl]-, monohydrochloride, (1a,5a,6b) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 831201-57-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-{6-[(1a,5a,6b)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl}-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 831201-84-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-{2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl}-2-pyridinyl]-3-methyl-, (1a,5a,6b) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-85-5 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-cyano-6-[5-{2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl}-2-pyridinyl]-, (1a,5a,6b) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-87-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1-aminocyclopropyl)carbonyl]-6-[5-{2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl}-2-pyridinyl]-, monohydrochloride, (1a,5a,6b) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-89-9 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[2-(4H-1,2,4-triazol-4-yl)ethyl]-, (1a,5a,6β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-90-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(4-morpholinylacetyl)-, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-94-6 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-, monohydrochloride, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831201-95-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-fluoro-2-pyrrolidinyl)carbonyl]-, monohydrochloride, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-91-3 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-(5-cyano-2-pyridinyl)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-93-5 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(2-pyrrolidinylcarbonyl)-, monohydrochloride, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-97-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6β)-6-amino-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, dihydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 831201-99-1 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(hydroxyacetyl)-, (1a,5a,6β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-04-1 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-cyano-6-[5-(2,6-difluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl)-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-05-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-(2,6-difluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl)-2-pyridinyl]-3-methyl-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-06-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1a,5a,6b)-6-(hydroxymethyl)-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-07-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-(2-fluoro-4-((5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl)phenyl)-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-09-6 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-(2-fluoro-4-((5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl)phenyl)-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831202-11-0 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-(2-fluoro-4-((5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl)phenyl)-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831202-13-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-(2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl)-2-pyridinyl]-3-(1-piperazinylacetyl)-, dihydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 831202-14-3 HCAPLUS  
 CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-thienyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-15-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1-piperidinylacetyl)-, (1a,5a,6β)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-16-5 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1-pyrrolidinylacetyl)-, (1a,5a,6β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831202-19-8 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-, monohydrochloride, (1a,5a,6β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831202-20-1 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-fluoro-2-pyrrolidinyl)carbonyl]-, (1a,5a,6β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-17-6 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[[4-(dimethylamino)-1-piperidinyl]acetyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-NMe2

RN 831202-18-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(2-pyrrolidinylcarbonyl)-, monohydrochloride, (1a,5a,6β)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 831202-21-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6β)-6-amino-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-22-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6β)-6-amino-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 831202-23-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6b)-6-amino-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-24-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6b)-6-amino-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-27-8 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-methyl-1-piperazinyl)acetyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-32-5 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[2-(acetyloxy)-1-[(acetyloxy)methyl]ethyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-33-6 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1S,3R,4S)-1-azabicyclo[2.2.1]hept-3-ylcarbonyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

Me

RN 831202-29-0 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3,3-dioxide, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-31-4 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3,3-dioxide, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-34-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(2-pyridinyl)-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-37-0 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(1,2,3,4-thiadiazol-5-yl)-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-42-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,5-trifluoro-4'-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-45-0 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2'-fluoro-4'-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-53-0 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1-aminocyclopropyl)carbonyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-57-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-3-[(2S)-2-pyrrolidinylcarbonyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-59-6 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-3-[(2S,4R)-4-hydroxy-2-pyrrolidinyl]carbonyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-63-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl)phenyl]-2-pyridinyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-64-3 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl)phenyl]-2-pyridinyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-66-5 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-3-[(2S)-2-pyrrolidinylcarbonyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-81-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831203-07-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[[[(2S,4S)-4-fluoro-2-pyrrolidinyl]carbonyl]-, monohydrochloride, (1a,5a,6β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831222-03-8 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3-oxide, (1a,5a,6β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831222-06-1 HCAPLUS  
 CN Carbamic acid, [(1a,3a,5a,6β)-6-[5-[2-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831221-99-9 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3-oxide, (1a,5a,6β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831222-02-7 HCAPLUS  
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3-oxide, (1a,5a,6β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831222-07-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6β)-6-amino-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831222-10-7 HCAPLUS  
 CN Carbamic acid, [(1a,3a,5a,6β)-6-[5-[2,6-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831222-11-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(1a,5a,6b)-6-amino-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 831202-60-9P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)  
 RN 831202-60-9 HCAPLUS  
 CN 1-Pyrrolidinylcarboxylic acid, 2-[[[(1a,5a,6b)-6-cyano-6-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-fluoro-, 1,1-dimethylethyl ester, (2S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 700370-33-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827628-21-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827628-35-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-iodophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—OBu-t

IT 501939-70-4P 501939-95-3P 700370-33-8P  
 827628-21-7P 827628-35-3P 831203-03-3P  
 831203-04-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)  
 RN 501939-70-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 831203-03-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-04-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 831202-93-8 831203-02-2  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of cyclopropyl-oxazolidinones as antibiotics)


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 831202-93-8 HCAPLUS  
 CN Methanesulfonic acid, trifluoro-, 2,6-difluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-02-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 831203-05-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of cyclopropyl-oxazolidinones as antibiotics)  
 RN 831203-05-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[(3-fluoro-4-iodophenyl)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 04 Jan 2005  
 AB Oxazolidinones represent a new and promising class of antibacterial agents. Current research in this area is mainly concentrated on improving the safety profile and the antibacterial spectrum. Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect. Recently, it was found that the 1,2,3-triazole is a good replacement for the conventional acetamide functionality found in oxazolidinones. The authors now disclose the finding that 1,2,3-triazoles bearing a substituent like Me, small substituted Me, bromo, or a linear (sp-hybridized) group at the 4 position are good antibacterials with reduced or no activity, within the detection limit of the assay, against MAO-A. The results are especially promising for the development of oxazolidinones with an improved safety profile. The MAO-A SAR can be rationalized on the basis of docking studies to a MAO-A/MAO-B homol. model.


ACCESSION NUMBER: 2005:3760 HCAPLUS  
 DOCUMENT NUMBER: 142:211423  
 TITLE: Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A  
 AUTHOR(S): Reck, Folkert; Zhou, Fei; Girardot, Marc; Kern, Gunther; Eyermann, Charles J.; Hales, Neil J.; Ramsay, Rona R.; Gravestock, Michael B.  
 CORPORATE SOURCE: AstraZeneca Discovery, AstraZeneca R&D Boston, Waltham, MA, 02451, USA  
 SOURCE: Journal of Medicinal Chemistry (2005), 48(2), 499-506  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 142:211423

IT 371195-02-7  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); FRP (Properties); BIOL (Biological study)  
 (identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)  
 RN 371195-02-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 827628-34-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of cyclopropyl-oxazolidinones as antibiotics)  
 RN 827628-34-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[(3,5-difluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


IT 591253-34-8P 591253-50-8P 591253-54-2P  
 591253-98-1P  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); FRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)  
 RN 591253-34-8 HCAPLUS  
 CN Phosphoric acid, 1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methyl] diphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-50-8 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 591253-54-2 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(2,2-dibromoethenyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-95-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(trimethylsilyl)ethynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 591231-84-4P 591231-97-9P 591232-00-7P  
 591253-26-9P 591253-36-0P 591253-50-0P  
 591253-77-9P 591253-78-0P 591253-81-5P  
 591253-82-6P 591253-94-0P 844493-91-0P

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-00-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-methyl-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-26-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 844493-92-1P

RI: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)  
 RN 591231-84-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(1-methylethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591231-97-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-ethyl-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-36-0 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-acetonitrile, 1-[[5R]-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-60-0 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-[(1E)-2-bromoethenyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-77-9 HCAPLUS  
CN 2-Oxazolidinone, 5-[(4-bromo-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-78-0 HCAPLUS  
CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-94-0 HCAPLUS  
CN 2-Oxazolidinone, 5-[(4-ethynyl-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 844493-91-0 HCAPLUS  
CN 2-Oxazolidinone, 5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-81-5 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-82-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 844493-92-1 HCAPLUS  
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[5R]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 ED Entered STN: 21 Oct 2004  
 GI



AB Title compds. I [A = oxazolyl, isoxazolyl, etc.; n = 0-1; Y = SOO-2, O, amino; Z = formyl, thioformyl, acyl, etc.; W = CH2, CO, oximino, etc.; R1 = H, OH, amino, etc.; R2-3 = H, F; R4-5 = H, Cl, F, Me, NH2, OH; R6-7 = H, alkyl] are prepared. For example, II is prepared in 9 steps from 2-fluoro-4-nitrobenzaldehyde. II has MIC = 4 µg/mL for *S. aureus* (UC3213). I are antibacterial agents.


ACCESSION NUMBER: 2004:872795 HCAPLUS  
 DOCUMENT NUMBER: 141:366217  
 TITLE: Preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivatives as antimicrobials  
 INVENTOR(S): Renslo, Adam Robert; Gordsev, Mikhail Fedor; Patel, Dinesh Vinobhai; Gao, Hongwu; Josyula, Vara Prasad Venkata Nagendra  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, LLC, USA  
 SOURCE: PCT Int. Appl., 187 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089943	A1	20041021	WO 2004-1B1135	20040330
WO 2004089943	C1	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,


L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-15-3 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane, 6-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-16-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-17-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2005192325 A1 20050901 US 2004-815589 20040401  
 PRIORITY APPL. INFO.: MARPAT 141:366217 P 20030409  
 OTHER SOURCE(S):  
 IT 777089-03-2P 777089-13-1P 777089-14-2P  
 777089-15-3P 777089-16-4P 777089-17-5P  
 777089-18-6P 777089-23-3P 777089-24-4P  
 780766-88-3P 780766-89-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)  
 RN 777089-83-2 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-13-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-14-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-


L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

Absolute stereochemistry.




RN 777089-18-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-23-3 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexan-2-one, 6-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1S,5R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-24-4 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexan-2-one, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1S,5R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 780766-88-3 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1a,5a,6b)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-89-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1a,5a,6b)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 777090-03-6P  
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
ED Entered STN: 30 Sep 2004  
GI



AB Title compds. (I: HET = pyrazolyl, imidazolyl, triazolyl, tetrazolyl; Q = (substituted) azolylphenyl, azolylpyridinyl, azolylloxazolyl, azolylthiazolyl, etc.), were prepared thus, (R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given), (PPh3)2PdCl2, and 5-tributylstannyl-3-methylisoxazole were heated together at 100° in dioxane for 16 h to give title compound (II). II showed a min. inhibitory concentration of 1 µg/mL against *Staphylococcus aureus* MSQ5 (methicillin resistant and quinolone resistant).

ACCESSION NUMBER: 2004:799584 HCAPLUS  
DOCUMENT NUMBER: 141:296028  
TITLE: Preparation of azolymethylloxazolidinones as antibacterials.  
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene  
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
SOURCE: PCT Int. Appl., 72 pp.  
CODEN: FIKXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083206	A1	20040930	WO 2004-GB1132	20040316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, BZ, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPL. INFO.: GB 2003-6357 A 20030320  
OTHER SOURCE(S): MARPAT 141:296028

IT 765286-96-2P 765286-97-3P 765286-98-4P  
765286-99-5P 765287-00-1P 765287-01-2P  
765287-02-3P 765287-03-4P 765287-04-5P  
765287-05-6P 765287-06-7P 765287-07-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

RN 777090-03-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
(prepn. of azolymethylloxazolidinones as antibacterials)


RN 765286-96-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-5-isoxazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765286-97-3 HCAPLUS  
CN 3-isoxazolecarboxylic acid, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765286-98-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-(hydroxymethyl)-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765286-99-5 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-[(phosphonomethyl)-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 765287-00-1 HCAPLUS  
CN 1H-Pyrazole-5-carbonitrile, 1-methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-01-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-1-ylmethyl)-5-(1H-1,2,3-triazol-1-ylmethyl)- (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765287-02-3 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-1-ylmethyl)-5-(1H-1,2,3-triazol-1-ylmethyl)- (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 765287-06-7 HCAPLUS  
CN 2H-1,2,3-Triazole-2-acetonitrile, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-18-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-[(phosphonomethyl)methyl]-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, disodium salt, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 Na


IT 501939-95-3P 765287-07-8P 765287-15-8P  
765287-16-8P 765287-17-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of azolymethylloxazolidinones as antibacterials)  
RN 501939-95-3 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 765287-03-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-methyl-1H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-04-5 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765287-05-6 HCAPLUS  
CN 1H-1,2,3-Triazole-1-acetonitrile, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



Absolute stereochemistry.


RN 765287-07-8 HCAPLUS  
CN Phosphoric acid, bis(1,1-dimethylethyl) [5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-15-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1-[(4-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-16-9 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-ethynyl-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.





RN 765287-17-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3-fluoro-4-((trimethylsilyl)ethynyl)phenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
ED Entered STN: 30 Sep 2004  
GI



AB Title compds. represented by the formula I [wherein N-HET = (un)substituted 1-pyrazolyl, 1-imidazolyl, 1,2,3-triazol-1-yl, etc.; Q = (un)substituted heteroaryl Ph, pyridinyl, thienyl, etc.] and pharmaceutically acceptable salts or an in-vivo hydrolyzable ester thereof] were prepared as MAO-A (mono-amine oxidase) inhibitors. For example, coupling reaction of (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one with 5-(tributylstannyl)-3-methylisoxazole gave II. II showed decreased MAO-A potency with KI value of 21 µg/mL. Thus, I and their pharmaceutical compds. are useful as antibacterial agents.

ACCESSION NUMBER: 2004:799583 HCAPLUS  
DOCUMENT NUMBER: 141:314336  
TITLE: Preparation of 1,3-oxazolidin-2-one derivatives as antibacterial agents  
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene  
PATENT ASSIGNER(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
SOURCE: PCT Int. Appl., 70 pp.  
DOCUMENT TYPE: CODEN: PIXXD2  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083205	A1	20040930	WO 2004-GB1119	20040316
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,			

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, HL, HR, NS, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-6358 A 20030320  
OTHER SOURCE(S): MARPAT 141:314336


IT 765912-32-1P 765912-34-3P 765912-36-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,3-oxazolidin-2-one derivs. as MAO-A inhibitors)


RN 765912-32-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3-fluoro-4-((3-methyl-5-isoxazolyl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765912-34-3 HCAPLUS  
CN 2-Oxazolidinone, 3-[(4-((3-isoxazolyl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765912-36-5 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3-fluoro-4-[(1-(phenylmethyl)-1H-1,2,3-triazol-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 501939-98-6P 501940-28-9P 765912-54-7P

765912-55-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1,3-oxazolidin-2-one derivs. as MAO-A inhibitors)


RN 501939-98-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-28-9 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765912-54-7 HCAPLUS  
CN 2-Oxazolidinone, 3-[(4-ethynyl-3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


Absolute stereochemistry.



RN 765912-55-8 HCAPLUS

CN 2-Oxazolidinone, 3-([3-fluoro-4-((trimethylsilyl)ethynyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


triazol-4-yl)methyl]-β-D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B



RN 756825-24-8 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3,6-dideoxy-3-(dimethylamino)-4-O-[2-[[1-[[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-oxopropyl]-β-D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 16 Sep 2004

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Bifunctional heterocyclic glycosides I were prepared, wherein X is a linear linker; Y is heterocyclic; J is H, macrocycle, acyl, Ln-alkyl, Ln-alkenyl, Ln-alkynyl; Ln-aromatic carbocycle, L is CO, CO<sub>2</sub>, amide; n is 0-1; R1-R3 are independently H, Ln-alkyl, Ln-alkenyl, Ln-alkynyl; Ln-aromatic; R2R3 together with the N atom to which they are bonded, form 5-7 membered saturated, unsatd., or aromatic heterocycle; useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. Thus, macrolide glycoside II was prepared as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agent (no biol. data).

ACCESSION NUMBER: 2004:756728 HCAPLUS

DOCUMENT NUMBER: 141:260999

TITLE: Preparation of bifunctional heterocyclic azithromycin compounds useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents

INVENTOR(S): Farmer, Jay J.; Sutcliffe, Joyce A.; Bhattacharjee, Ashoke

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078770	A1	20040916	WO 2004-US6892	20040305
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, RW, SA, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VJ, VN, YU, ZA, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2517970	AA	20040916	CA 2004-2517970	20040305
PRIORITY APPLN. INFO.:				
			US 2003-451951P	P 20030305
			WO 2004-US6892	W 20040305

OTHER SOURCE(S): MARPAT 141:260999

IT 756825-22-6P 756825-24-6P 756825-28-9P

756825-28-6P

RL: BSU (Biological study, unclassified); IMF (Industrial manufacture);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bifunctional heterocyclic azithromycin compds. useful as


antiinfective antiproliferative antiinflammatory and prokinetic agents)

RN 756825-22-6 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3,6-dideoxy-3-(dimethylamino)-4-O-[2-[[1-[[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 756825-25-9 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3,6-dideoxy-3-(dimethylamino)-4-O-[2-[[1-[[[5R]-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-β-D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 756825-26-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3,6-dideoxy-3-(dimethylamino)-4-O-[[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]carbonyl]-β-D-glucopyranosyl]oxy]-13-[[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A





PAGE 1-B



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 16 Sep 2004  
 GI



AB The title comps. I [R1 = -NH(C=O)R5 or (substituted)1,2,3-Triazolyl; W = O or S; R2, R3 = H, F, Cl, CF3, OMe, SMe, and Et; R5 = H, alkyl, Me, 5-halo-2-thienyl, etc.; R4 = hydroxymethyl] were prepared as antibacterial agents. For example, compound II was prepared from (5R)-3-(3-fluorophenyl)-5-hydroxymethyl-oxazolidin-2-one in a multi-step synthesis. Antibacterial properties of II against several types of bacteria were determined [MIC(μg/mL): methicillin sensitive and quinolone sensitive staphylococcus aureus (0.25), methicillin resistant and quinolone resistant staphylococcus aureus (0.5), streptococcus pneumoniae (0.02), haemophilus influenza (4), and Moraxella catarrhalis (0.5)].


ACCESSION NUMBER: 2004:756715 HCAPLUS  
 DOCUMENT NUMBER: 141:260739  
 TITLE: Preparation of hydroxymethyl dihydroisoxazole derivatives useful as antibiotic agents  
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Carcanague, Daniel Robert  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 107 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078753-	A1	20040916	WO 2004-GB730	20040224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BH, CH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CA 2517706 AA 20040916 CA 2004-2517706 20040224  
 PRIORITY APPLN. INFO.: GB 2003-4723 A 20030301  
 GB 2003-18607 A 20030808  
 WO 2004-GB730 W 20040224


OTHER SOURCE(S): MARPAT 141:260739  
 IT 702681-58-1P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)  
 RN 702681-58-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 756873-54-8P 756873-57-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)  
 RN 756873-54-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5R)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 756873-57-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-95-3P 700370-33-8P 700370-36-1P  
 700370-37-2P 700370-39-4P 700370-40-7P  
 756874-06-3P 756874-09-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)  
 RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-33-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 700370-40-7 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(bromomethyl)-1H-1,2,3-triazol-1-ylmethyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756874-06-3 HCAPLUS  
 CN Phosphoric acid, bis[(1,1-dimethylethyl) [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 700370-36-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-37-2 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-39-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(hydroxymethyl)-1H-1,2,3-

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 756874-09-6 HCAPLUS  
 CN β-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B

IT 756873-76-4P 756873-84-4P 756873-87-7P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (pro-drug; preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)  
 RN 756873-76-4 HCAPLUS  
 CN Glycine, N,N-dimethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-

# Ngrazier 10671326Amend2

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
isoxazoly]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 756873-84-4 HCAPLUS  
CN Pentanoic acid, 5-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazoly]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
756874-04-1P 756874-05-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(pro-drug; prepn. of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)  
RN 702681-56-9 HCAPLUS  
CN β-Alanine, N,N-diethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazoly]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


—NEt2

RN 702681-66-1 HCAPLUS  
CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazoly]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

PAGE 1-B



RN 756873-87-7 HCAPLUS  
CN Pentanoic acid, 5-(methylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazoly]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

—NMe


IT 702681-56-9P 702681-66-1P 702682-78-8P  
756873-58-2P 756873-59-3P 756873-60-6P  
756873-61-7P 756873-62-8P 756873-63-9P  
756873-64-0P 756873-65-1P 756873-66-2P  
756873-67-3P 756873-68-4P 756873-69-5P  
756873-70-6P 756873-71-9P 756873-72-0P  
756873-73-1P 756873-74-2P 756873-75-3P  
756873-77-5P 756873-78-6P 756873-79-7P  
756873-80-0P 756873-81-1P 756873-82-2P  
756873-83-3P 756873-85-5P 756873-86-6P  
756873-88-8P 756873-89-9P 756873-91-3P  
756873-92-4P 756873-93-5P 756873-94-6P  
756873-95-7P 756873-96-8P 756873-97-9P  
756873-98-0P 756873-99-1P 756874-00-7P  
756874-01-8P 756874-02-9P 756874-03-0P

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 702682-78-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(2-methoxyethoxy)methoxy]methyl]-3-isoxazoly]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

—OMe

RN 756873-58-2 HCAPLUS  
CN Hexanedioic acid, ethyl [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazoly]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




PAGE 1-B

OEt

RN 756873-59-3 HCAPLUS  
 CN  $\beta$ -Alanine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-60-6 HCAPLUS  
 CN Butanoic acid, 4-(dimethylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




RN 756873-62-8 HCAPLUS  
 CN Acetic acid, methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-63-9 HCAPLUS  
 CN Propanoic acid, 3-methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-64-0 HCAPLUS  
 CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Absolute stereochemistry.

PAGE 1-B


OMe

RN 756873-61-7 HCAPLUS  
 CN Pentanoic acid, 5-[(methoxycarbonyl)amino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-65-1 HCAPLUS  
 CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


OMe

RN 756873-66-2 HCAPLUS  
 CN Pentanedioic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B

OMe

RN 756873-67-3 HCAPLUS  
 CN Butanoic acid, 4-methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, diammonium salt, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 NH3

RN 756873-71-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(sulfoxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-72-0 HCAPLUS  
 CN 4-Piperidinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-B

OMe


RN 756873-68-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(acetyloxy)methyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-69-5 HCAPLUS  
 CN 1,2-Cyclohexanedicarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-70-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(phosphonoxy)methyl]-3-



RN 756873-73-1 HCAPLUS  
 CN Pentanoic acid, 5-(dimethylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


NMe2

RN 756873-74-2 HCAPLUS  
 CN Butanedioic acid, mono[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

-CO<sub>2</sub>H

RN 756873-75-3 HCAPLUS  
 CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A

● Cl<sup>-</sup>

RN 756873-79-7 HCAPLUS  
 CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl 3-methoxypropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

-(CH<sub>2</sub>)<sub>3</sub>OMe

RN 756873-80-0 HCAPLUS  
 CN Pyrazinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B

=O

RN 756873-77-5 HCAPLUS  
 CN Pentanoic acid, 5-[(ethoxycarbonyl)amino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 756873-78-6 HCAPLUS  
 CN Ethanaminium, 2-[[[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methoxy]-N,N,N-trimethyl-2-oxo-, chloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 756873-81-1 HCAPLUS  
 CN 5-Pyrimidinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756873-82-2 HCAPLUS  
 CN Ethanaminium, 2-[[[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methoxy]carbonyl]oxy]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

● Cl<sup>-</sup>


PAGE 1-B

N<sup>+</sup>Me<sub>3</sub>

RN 756873-83-3 HCAPLUS  
 CN Pentanoic acid, 5-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-A

PAGE 1-A




PAGE 1-B



RN 756873-88-8 HCAPLUS  
 CN Pentanoic acid, 5-[(dimethylamino)acetyl]methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 756873-85-5 HCAPLUS  
 CN Butanoic acid, 4-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 756873-86-6 HCAPLUS  
 CN Hexanoic acid, 6-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-B



RN 756873-89-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(5S)-5-[(β-D-glucopyranosyloxy)methyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756873-91-3 HCAPLUS  
 CN Glycine, N-methyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 756873-92-4 HCAPLUS  
 CN L-Alanine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756873-93-5 HCAPLUS  
 CN L-Valine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 756873-96-8 HCAPLUS  
 CN L-Isoleucine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756873-97-9 HCAPLUS  
 CN L-Glutamine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 756873-94-6 HCAPLUS  
 CN L-Leucine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 756873-95-7 HCAPLUS  
 CN Glycine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




PAGE 1-B



RN 756873-98-0 HCAPLUS  
 CN L-Aspartic acid, 1-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

CO2H

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 756873-99-1 HCAPLUS  
 CN L-Aspartic acid, 4-[[[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


CO<sub>2</sub>H

RN 756874-00-7 HCAPLUS  
 CN L-Lysine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 756874-03-0 HCAPLUS  
 CN Acetic acid, [2-[(methoxycarbonyl)methylamino]ethoxy]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 756874-04-1 HCAPLUS  
 CN Acetic acid, [2-(methylamino)ethoxy]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




PAGE 1-B



RN 756874-01-8 HCAPLUS  
 CN L-Phenylalanine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756874-02-9 HCAPLUS  
 CN L-Proline, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


PAGE 1-B



RN 756874-05-2 HCAPLUS  
 CN L-Isoleucine, N-methyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
ED Entered STN: 23 Jul 2004  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I (R1-R8 = H, halo, NH2, glycolamino, (un)substituted alkoxy; T, Q = halo, OH, (un)substituted C1-8 alkoxy, (un)substituted C1-8 alkanoyloxy, NH2, N3, (un)substituted unsatd. heterocyclyl, etc.), useful for controlling (drug-resistant) bacteria, are prepared by conversion of 3-(substituted phenyl)-2-oxo-5-oxazolidinyls II (R1-R4, Q = same as above; X = iodine, Br, Cl, haloalkylsulfonyloxy, diaryl phosphate residue) into 3-(boron-substituted phenyl)-2-oxo-5-oxazolidinyls III (R1-R4, Q = same as above; X = BR9R10; R9, R10 = OH, C1-8 linear alkyl(oxy), C3-8 branched alkyl(oxy); R9R10 may be linked), then coupling with oxazolidinylbenzenes III (R5-R8, T = same as above; Y = iodine, Br, Cl, haloalkylsulfonyloxy, diaryl phosphate residue). Thus, coupling of 3-(3-fluoro-4-iodophenyl)-2-oxo-5(R)-phthalimidomethyl-2-oxazolidinyl with 5(S)-acetamidomethyl-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-5-oxazolidinyl in the presence of K phosphate and tetrakis(triphenylphosphine)palladium in DMF gave the corresponding biphenyl compound with 66% yield, which showed MIC of 2 µg/mL against methicillin-resistant *Staphylococcus aureus*.


ACCESSION NUMBER: 2004:588234 HCAPLUS  
DOCUMENT NUMBER: 141:140417  
TITLE: Preparation of novel biphenyls, their intermediates, and their use as bactericides  
INVENTOR(S): Shiokawa, Sojiro; Ishikawa, Makoto; Yanagisawa, Yumiko; Kawaguchi, Masami; Fujita, Toshiaki; Maehashi, Kazunori; Yoshida, Satoshi  
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 185 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004203809	A2	20040722	JP 2002-376218	20021226
PRIORITY APPLN. INFO.:			JP 2002-376218	20021226

OTHER SOURCE(S): MARPAT 141:140417  
IT 724793-19-5P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of (oxo-oxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)  
RN 724793-19-5 HCAPLUS  
CN Carbamic acid, [[1-[[[(5R)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



PAGE 1-B


IT 724792-94-3P 724793-13-9P 724793-15-1P  
724793-20-8P 724793-78-6P 724793-79-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of (oxo-oxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)  
RN 724792-94-3 HCAPLUS  
CN Acetamide, N-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-13-9 HCAPLUS  
CN Carbamic acid, [2-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.




PAGE 1-B

OBu-t  
RN 724793-15-1 HCAPLUS  
CN Acetamide, 2-amino-N-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1  
CRN 724793-14-0  
CMF C24 H23 F2 N7 O5

Absolute stereochemistry.




CH 2  
CRN 76-05-1

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CMF C2 H F3 O2

RN 724793-20-8 HCAPLUS  
CN Acetamide, N-[[[(5S)-3-[[4'-[(5R)-5-[[5-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724793-78-6 HCAPLUS  
CN Carbamic acid, [[1-[[[(5R)-3-[[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 724793-79-7 HCAPLUS  
CN Acetamide, N-[[[(5S)-3-[[4'-[(5R)-5-[[4-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-95-3P 724793-90-2P 724793-91-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of (oxoxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)  
RN 501939-95-3 HCAPLUS  
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 724793-90-2 HCAPLUS  
CN Carbamic acid, [[1-[[[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 724793-91-3 HCAPLUS  
CN Carbamic acid, [[1-[[[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
ED Entered STN: 09 Jul 2004  
GI




AB The invention relates to a preparation of oxazolidinone derivs. of formula R1-A-C-B-CH2-R2 [wherein: A and B are independently selected from oxazolidinone or isoxazole derivs.; C is a biaryl group C1-C2 where C1 is benzene-1,4-diyl, thiene-2,5-diyl, or pyridine-2,5-diyl, etc., and C2 is pyridazine-3,6-diyl, pyrazine-2,5-diyl, pyrimidine-2,5-diyl, or 1,3,4-thiadiazole-2,5-diyl, etc.; R1 is CN, C(O), (un)substituted Ph or naphthyl, cycloalkyl, or heteroaryl, etc.; R2 is OH, OSi(trialkyl), or NHC(O)Me, etc.], useful as antibacterial agents. For instance, oxazolidinone derivative I was prepared from the obtained bromopyrimidine derivative

II and obtained trimethylstannylphenyloxazole derivative III in the presence of palladium catalyst. For instance, antibacterial properties of I against several types of bacteria were determined [MIC(μg/mL): staphylococcus aureus (2), streptococcus pneumoniae (0.25), haemophilus influenza (8)].


ACCESSION NUMBER: 2004:550955 HCAPLUS  
DOCUMENT NUMBER: 141:89124  
TITLE: A preparation of oxazolidinone derivatives, useful as antibacterial agents  
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Rhynch, Hoan Khai  
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
SOURCE: PCT Int. Appl., 117 pp.  
CODEN: FIKXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 700370-36-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-37-2 HCAPLUS  
CN 2-Oxazolidinone, 5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-39-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056817	A1	20040708	WO 2003-GB5448	20031215
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EG, EH, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1572688	A1	20050914	EP 2003-768000	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: GB 2002-29526 A 20021219 WO 2003-GB5448 W 20031215				

OTHER SOURCE(S): MARPAT 141:89124  
IT 501939-94-2P 501939-95-3P 700370-36-1P  
700370-37-2P 700370-39-4P 700370-40-7P  
716379-10-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of oxazolidinone derivs., useful as antibacterial agents)  
RN 501939-94-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[[3-fluoro-4-(trimethylstannyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-95-3 HCAPLUS  
CN 2-Oxazolidinone, 3-[[3-fluoro-4-(iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 700370-40-7 HCAPLUS  
CN 2-Oxazolidinone, 5-[[4-(bromomethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 716379-10-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




IT 716379-02-1P 716379-05-4P 716379-09-8P  
716379-12-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of oxazolidinone derivs., useful as antibacterial agents)  
RN 716379-02-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-[2-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-5-




L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 pyrimidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 716379-05-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-{2-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-5-thiazolyl}phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 716379-09-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-{6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)



RN 716379-12-3 HCAPLUS

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 10 Jun 2004  
 GI



II


AB Title compds. (R1a)n-A-C-B-CH2-R1b (C = biaryl group; A, B = dihydroisoxazole, oxazolidinone; R1a = CN, carboxy, alkoxycarbonyl, aryl, etc.; n = 0-2; R1b = OH, silyloxy, etc.). I] are prepared. For instance, (5R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given) is coupled to 5,5-bis[[(tert-butylidimethylsilyl)oxy)methyl]-3-{4-(trimethylstannyl)phenyl}-4,5-dihydroisoxazole (preparation given) (NMP, (furan-2-yl)3P, dba3Pd2) and the resulting adduct desilylated (THF, TBAF) to give II. II exhibits MIC = 0.5 µg/ml against *Staphylococcus aureus*; compds. of the invention are antibacterial agents.

ACCESSION NUMBER: 2004:467903 HCAPLUS  
 DOCUMENT NUMBER: 141:38599  
 TITLE: Preparation of oxazolidinone/isoxazoline derivatives as antibacterial agents  
 INVENTOR(S): Carcanague, Daniel Robert; Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene; Weber, Thomas Peter  
 PATENT ASSIGNEE(S): AstraZeneca AB, Sued.; AstraZeneca UK Limited  
 SOURCE: PCT Int. Appl., 185 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048392	A1	20040610	WO 2003-GB5087	20031124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Oxazolidinone, 3-[4-{2-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-5-pyrimidinyl]-3-fluorophenyl]-5-{[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl}-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CA 2507469 AA 20040610 CA 2003-2507468 20031124  
 EP 1567532 A1 20050931 EP 2003-811807 20031124  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003016688 A 20051018 BR 2003-16688 20031124  
 PRIORITY APPLN. INFO.: GB 2002-27702 A 20021128  
 GB 2003-4725 A 20030301  
 GB 2003-18608 A 20030808  
 WO 2003-GB5087 W 20031124

OTHER SOURCE(S): MARPAT 141:38599  
 IT 501940-91-6P 702679-77-4P, (5R)-3-[4'-[5,5-Bis[[(tert-butylidimethylsilyl)oxy)methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one  
 702679-98-9P, (5R)-3-[4'-[5,5-Bis[[(tert-butylidimethylsilyl)oxy)methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 702680-89-8P 702680-93-1P 702681-83-2P, (5R)-3-[4-[16-[(5S)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (Preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)  
 RN 501940-91-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702679-77-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702679-98-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-89-5 HCAPLUS  
 CN 5-Isoxazolecarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-93-1 HCAPLUS  
 CN 5-Isoxazolecarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-83-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[6-[(5S)-5-[(1R)-1,2-dihydroxymethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 702679-95-6P, (5R)-3-[4'-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-03-3P,  
 (5R)-3-[4'-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-11-3P 702680-16-8P, (5R)-3-[4'-[4,5-Dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-21-5P,  
 (5R)-3-[4'-[4,5-Dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-23-7P,  
 (5R)-3-[4'-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-38-1P, (5R)-3-[4'-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-46-4P 702680-51-1P 702680-61-3P,  
 702680-65-7P 702680-69-1P 702680-73-7P,  
 (5R)-3-[3-Fluoro-4-[6-[(5S)-5-bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]phenyl]-5-[(4-fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-85-1P 702680-95-3P  
 702680-99-7P 702681-01-4P 702681-07-0P  
 702681-13-6P 702681-15-0P 702681-20-7P  
 702681-22-9P 702681-26-3P 702681-31-0P  
 702681-39-6P 702681-40-1P 702681-42-3P  
 702681-44-6P 702681-47-6P 702681-54-7P  
 702681-56-9P 702681-61-6P 702681-64-9P  
 702681-66-1P 702681-69-4P 702681-71-0P  
 702681-73-0P 702681-87-6P, (5R)-3-[4'-[6-[(5R)-5-[(1R)-1,2-dihydroxymethyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702681-97-8P  
 (5R)-3-[4'-[6-[(5S)-5-[(1S)-1,2-dihydroxymethyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-01-7P, (5R)-3-[4'-[6-[(5R)-5-[(1S)-1,2-dihydroxymethyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-13-1P,  
 (5R)-3-[4'-[6-[(5S)-5-bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-26-6P 702682-29-9P  
 702682-32-4P 702682-43-7P, (5R)-3-[3-Fluoro-4-[6-[(5S)-5-[(2-hydroxymethyl)thio]methyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-56-2P 702682-72-2P 702682-78-8P  
 702682-88-0P


L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); TEU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of oxazolidinone/isoxazoline derivs. as antibacterial agents)  
 RN 702679-95-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-03-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-11-3 HCAPLUS  
 CN 5-Isoxazoleacetone, 3-[2'-fluoro-4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-16-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4'-((4,5-dihydro-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl)-5-((4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-21-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4'-((4,5-dihydro-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl)-5-((1H-1,2,3-triazol-1-yl)methyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-46-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4'-[6-[[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-1-oxido-3-pyridinyl]-3-fluorophenyl]-5-((1H-1,2,3-triazol-1-yl)methyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-51-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4'-[6-[[4,5-dihydro-5-(tetrahydro-3-hydroxy-1,1-dioxido-3-thienyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-((1H-1,2,3-triazol-1-yl)methyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-23-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-((1H-1,2,3-triazol-1-yl)methyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-35-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-((4-fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-61-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4'-[6-[[4,5-dihydro-5-(1-hydroxy-1-methylethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-((1H-1,2,3-triazol-1-yl)methyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-65-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4'-[6-[[4,5-dihydro-4,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-((1H-1,2,3-triazol-1-yl)methyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-69-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[5-(2,2-diethoxyethyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-73-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-99-7 HCAPLUS  
 CN 5-Isoxazolecarboxamide, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-N-methyl-, (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-01-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[(2-hydroxyethyl)sulfonylmethyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-85-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[5-[4,5-dihydro-5-(2-hydroxyethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-95-3 HCAPLUS  
 CN 5-Isoxazolecarboxamide, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-N,N-dimethyl-, (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-07-0 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxyphenylmethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-11-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(1-hydroxycyclopentyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-15-0 HCAPLUS  
 CN 1-Naphthaleneacetic acid, 1-[3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 702681-26-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(4-hydroxy-1-methyl-4-piperidinyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-31-0 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[[[2-(4-pyridinyl)ethyl]sulfonyl]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 702681-20-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(1-hydroxy-2-methylpropyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-22-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[[[2-(4-pyridinyl)ethyl]amino]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 702681-39-8 HCAPLUS  
 CN Glycine, N,N-dimethyl-, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 702681-40-1 HCAPLUS  
 CN Pentadecanoic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-


L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-  
isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-42-3 HCAPLUS  
CN 2,5,8,11,14-Pentaoxapentadecanoic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



PAGE 1-B


RN 702681-44-5 HCAPLUS

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-56-9 HCAPLUS  
CN β-Alanine, N,N-diethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

Net2


RN 702681-61-6 HCAPLUS  
CN Butanedioic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 702681-60-5  
CMF C26 H25 F N6 O7


L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN 4-Piperidinecarboxylic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-47-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[(phosphonomoyl)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, diammonium salt, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 NH3

RN 702681-54-7 HCAPLUS  
CN Propanoic acid, 2,2-dimethyl-, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

OMe

CH 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 702681-64-9 HCAPLUS  
CN Butanedioic acid, ethyl [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 702681-63-8  
CMF C27 H27 F N6 O7

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

-OEt


CH 2  
CRN 76-05-1  
CHF C2 H F3 O2



RN 702681-66-1 HCAPLUS  
CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 702681-69-4 HCAPLUS  
CN Propanoic acid, 2,2-dimethyl-, [(3-[5-[2-fluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methoxy)methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1  
CRN 702681-68-3  
CHF C27 H29 F N6 O6

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

-Bu-t

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CH 2  
CRN 76-05-1  
CHF C2 H F3 O2




RN 702681-71-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[(4-nitrobenzoyl)oxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-((1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

-CO2H

RN 702681-87-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[6-[(5R)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-((1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-97-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(1S)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-((1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

-NO2

RN 702681-73-0 HCAPLUS  
CN Butanedioic acid, mono[(3-[5-[2-fluoro-4-[(5R)-2-oxo-5-((1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-01-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5R)-5-[(1S)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-13-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 702682-29-9 HCAPLUS  
 CN Carbonic acid, (2R)-2-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-hydroxyethyl 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-21-1 HCAPLUS  
 CN Propanoic acid, 3-methoxy-, (2R)-2-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-hydroxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OMe

RN 702682-26-6 HCAPLUS  
 CN 3-Pyridinecarboxylic acid, (2R)-2-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-hydroxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




RN 702682-32-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[5-[(1R)-1,2-bis(phosphonoxy)ethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, tetraammonium salt, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

NH<sub>3</sub>

RN 702682-43-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(2-hydroxyethylthio)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-56-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(trifluoromethoxy)methyl]-3-




L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-72-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-{6-[(5S)-4,5-dihydro-5-[(2,2,2-trifluoroethoxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702682-78-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-{6-[(5S)-4,5-dihydro-5-[(2-methoxyethoxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 501940-27-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-36-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-95-3P, (5R)-3-(3-Fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-28-9P, (5R)-3-(3-Fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-33-8P 700370-37-2P

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

—OMe

RN 702682-88-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-{6-[(5S)-4,5-dihydro-5-(methoxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-98-6, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-27-8, (5R)-3-(3-Fluoro-4-(trimethylstannyl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-36-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)  
RN 501939-98-6 HCAPLUS  
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

702680-25-9P, (5R)-3-[4'-[5,5-Bis[(tert-butylidimethylsilyl)oxyl)methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-37-3P, (5R)-3-[4'-[5,5-Bis[(tert-butylidimethylsilyl)oxyl)methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-97-3P 702681-49-0P 702681-58-1P 702681-85-4P 702681-99-0P 702682-16-4P, (5R)-3-[4-[6-[5,5-Bis[(tert-butylidimethylsilyl)oxyl)methyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-35-7P 702682-37-9P 702682-47-1P, (5R)-3-[4-[6-[(5S)-5-(Chloromethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of oxazolidinone/isoxazoline derivs. as antibacterial agents)


RN 501939-95-3 HCAPLUS  
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-28-9 HCAPLUS  
CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 700370-33-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-37-2 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-[(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-25-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-49-0 HCAPLUS  
 CN Phosphoric acid, bis(1,1-dimethylethyl) [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-58-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-37-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-97-5 HCAPLUS  
 CN 5-Isomazolecarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-85-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-99-0 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-16-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702682-35-7 HCAPLUS  
 CN Phosphoric acid, (1R)-1-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-1,2-ethanediy] tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-37-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(1R)-1,2-bis(phosphonoxy)ethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702682-47-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-(chloromethyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 10 Jun 2004  
 GI




AB Isoxazolinyl oxazolidinone compds. of formula I (R1CH2-A-C-B-CH2R2 [A, B = oxazolidinone, isoxazolinone; C = (substituted) biaryl group; R1, R2 = OH, trialkylsilyloxy, acyloxy, heteroaryl, etc.]) are prepared as antibacterial agents. Methods for making compds. of formula I, compds. containing them and their use as antibacterial agents are also described. Thus, II was prepared, and had MIC of 0.5 µg/mL against *Staphylococcus aureus*.

ACCESSION NUMBER: 2004:467887 HCAPLUS  
 DOCUMENT NUMBER: 141:23522  
 TITLE: Preparation of isoxazolinyl oxazolidinone antibacterial agents  
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James  
 PATENT ASSIGNER(S): Astrazeneca AB, Sweden; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048370	A1	20040610	WO 2003-GB5082	20031124
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BV, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1567521	A1	20050831	EP 2003-811806	20031124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPL. INFO.: GB 2002-27701 A 20021128 WO 2003-GB5082 W 20031124				


OTHER SOURCE(S): MARPAT 141:23522  
 IT 698981-84-9P 698981-94-1P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of isoxazolinyl oxazolidinone antibacterial agents)  
 RN 698981-84-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

L12 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.



RN 698981-94-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[4'-[5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 698981-89-4P 698981-99-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of isoxazolinyloxazolidinone antibacterial agents)  
RN 698981-89-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 698981-99-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)



Absolute stereochemistry.



IT 501939-95-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of isoxazolinyloxazolidinone antibacterial agents)  
RN 501939-95-3 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
ED Entered STN: 10 Jun 2004  
GI



II

AB Title compds. I [C = substituted biaryl; R1 = HET1, HET2; HET1 = N-linked 5-membered (un)saturated heterocyclic ring, etc.; HET2 = N-linked 6-membered dihydroheteroaryl ring, etc.] are prepared. For instance, (5R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given) is coupled to bis(pinacolato)diboron (DMSO, PdCl2(dppf)·CH2Cl2, K2CO3) and the resulting adduct coupled to 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (DMF, H2O, K2CO3, (PPh3)4Pd) to give II. Compds. of the invention exhibit antibacterial activity with MIC = 0.01 - 256 µg/mL; II has MIC < 0.06 for Streptococcus pneumoniae.

ACCESSION NUMBER: 2004:467876 HCAPLUS  
DOCUMENT NUMBER: 141:23521  
TITLE: Preparation of substituted oxazolidinones as antibiotics  
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei  
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
SOURCE: PCT Int. Appl., 96 pp.  
CODEN: PIXXDZ  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048350	A2	20040610	WO 2003-GB5091	20031124
WO 2004048350	A3	20041021		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MD, MR, NE, SN, TD, TG

CA 2507628 A2 20051005 EP 2003-778506 20031124

EP 1581524 A2 20051005 EP 2003-778506 20031124

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, ER, HU, SK

BR 2003016690 A 20051018 BR 2003-16690 20031124

PRIORITY APPLN. INFO.: GB 2002-27704 A 20021128

GB 2003-10828 A 20030510

WO 2003-GB5091 W 20031124

OTHER SOURCE(S): MARPAT 141:23521

IT 700370-32-7P, (5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one] 700370-38-0P, (5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-41-8P, (5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-5-[(4-chloro-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one] 700370-44-1P, (5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-1-oxopyridin-3-yl]phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one] 700370-46-3P, (5R)-3-[3-fluoro-4-[6-[2-(2-hydroxyethyl)-2H-1,2,3,4-tetrazol-5-yl]-3-pyridinyl]phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-one] 700370-48-5P, (5R)-3-[3-fluoro-4-[6-[1-(propane-1,3-diol-2-yl)-1H-1,2,3,4-tetrazol-5-yl]-3-pyridinyl]phenyl]-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 700370-51-0P, (5R)-5-[(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-1,3-oxazolidin-2-one 700370-55-4P, (5R)-3-[3-fluoro-4-[2-methyl-6-(4-methyl-1H-1,2,3-triazol-1-yl)pyridin-3-yl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TEU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of substituted oxazolidinones as antibiotics)

RN 700370-32-7 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-35-0 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-41-8 HCAPLUS

CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-44-1 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 700370-46-3 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-(2-hydroxyethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 700370-48-5 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[1-(2-hydroxy-1-(hydroxymethyl)ethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one]

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




Absolute stereochemistry.

RN 700370-51-0 HCAPLUS

CN 2-Oxazolidinone, 5-[(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-55-4 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[2-methyl-6-(4-methyl-1H-1,2,3-triazol-1-yl)-3-pyridinyl]phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 700370-42-9, (5R)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of substituted oxazolidinones as antibiotics)  
 RN 700370-42-9 HCAPLUS  
 CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-95-3P, (5R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 700370-33-8P 700370-34-9P  
 700370-36-1P, (5R)-3-(3-fluoro-4-iodophenyl)-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-37-2P,  
 (5R)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 700370-38-3P 700370-39-4P, (5R)-3-(3-fluoro-4-iodophenyl)-5-[(4-hydroxymethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-40-7P, (5R)-3-(3-fluoro-4-iodophenyl)-5-[(4-bromomethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 700370-43-0P, (5R)-3-(3-fluoro-4-iodophenyl)-5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-52-1P,  
 (5R)-5-[(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-oxazolidin-2-one  
 700370-53-2P, (5R)-5-[(4-(difluoromethyl)-1H-1,2,3-triazol-1-

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 700370-36-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-37-2 HCAPLUS  
 CN 2-Oxazolidinone, 5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-38-3 HCAPLUS  
 CN Boronic acid, [2-fluoro-4-[(5R)-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Page 10429/11/2005

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


yl)methyl]-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one  
 700370-54-3P, 1-[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]-1H-1,2,3-triazole-4-carboxaldehyde  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREF (Preparation); RACT (Reactant or reagent)  
 (prepn. of substituted oxazolidinones as antibiotics)  
 RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-33-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-34-9 HCAPLUS  
 CN Boronic acid, [2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 700370-39-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-40-7 HCAPLUS  
 CN 2-Oxazolidinone, 5-[(4-(bromomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-iodophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 700370-43-0 HCAPLUS


L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Oxazolidinone, 5-[[4-(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-52-1 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-53-2 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 23 Apr 2004  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [R2, R3 = H, F, R4, R5 = H, Cl, F, etc.; R6, R7 = H, F, OH, etc.; R8 = H, F, OH, etc.; A = 5-methyl-2-oxazolidinonyl, 4,5-dihydro-5-Me-oxazoly], dihydro-5-Me-2(3H)-furanonyl, etc.; B = (CH2)<sub>n</sub>; n = 0-1; X = N, CH, Y = N, O, S; Z = NHCOR1, NHCOR1, CONHR1, etc.; R1 = H, NH2, NH-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of CBZ-protected benzenamine II, e.g., prepared from benzyl 3-pyrroline-1-carboxylate in 5-steps, and (S)-acetic acid 2-acetylamino-1-chloromethyl ethyl ester afforded oxazolidinone III in 62% yield. In *S. aureus* Min. inhibitory concentration (MIC) growth studies, 6-examples of compds. I exhibited MIC values ranging from 1-8 µg/mL, i.e., the MIC value of oxazolidinone III was 1 µg/mL. Compds. I are claimed useful for the treatment of skin and eye infections.

ACCESSION NUMBER: 2004:333714 HCAPLUS  
 DOCUMENT NUMBER: 140:357327  
 TITLE: Preparation of bicyclic[3.1.0]oxazolidinones and related compounds as antibacterial agents  
 INVENTOR(S): Gordeev, Mikhail Fedor; Rensio, Adam; Patel, Dinesh Vinodhrai  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 156 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033451	A1	20040422	WO 2003-US28560	20031003
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004127530	A1	20040701	US 2003-677451	20031002
US 6875784	B2	20050405		
CA 2501352	AA	20040422	CA 2003-2501352	20031003
EP 1549641	A1	20050706	EP 2003-770310	20031003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015106	A	20050809	BR 2003-15106	20031003
PRIORITY APPLN. INFO.:				
US 2002-417735P P 20021009				
WO 2003-US28560 W 20031003				


OTHER SOURCE(S): MARPAT 140:357327  
 IT 681424-73-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-54-3 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[[5-(3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl)methyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (prepn. of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)


RN 681424-73-7 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1a,5a,6a)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 681424-72-6

CHF C18 H17 F2 N5 O4

Absolute stereochemistry.



CH 2

CRN 76-05-1

CHF C2 H F3 O2




IT 681425-60-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)


RN 681425-60-5 HCAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
ED Entered STN: 23 Apr 2004  
GI

AB Oxopyridinylphenyl oxazolidinones, e.g. of formula I [W = O, S; R<sup>1</sup> = NH<sub>2</sub>, NH-alkyl, alkyl, alkoxy, etc.; R<sub>2</sub>, R<sub>3</sub> = H, Cl, F, Me, NH<sub>2</sub>, OH; R<sub>4</sub> = H, halo, NH<sub>2</sub>, OH, CN, alkyl, alkoxy, etc.], are prepared as antibacterial agents which have activity against both Gram-pos. and Gram-neg. bacteria. Thus, I was prepared, and had MIC of 1 µg/mL against HINF 30063.

ACCESSION NUMBER: 2004:333712 HCAPLUS  
DOCUMENT NUMBER: 140:339319  
TITLE: Preparation of oxopyridinylphenyl oxazolidinones as Gram-positive and Gram-negative antibacterial agents  
INVENTOR(S): Gordeev, Mikhail Fedor; Singh, Upinder; Patel, Dinesh Vinodhai; May, Paul Dennis  
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
SOURCE: PCT Int. Appl., 53 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033449	A1	20040422	WO 2003-IB4380	20031003
W: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499105	AA	20040422	CA 2003-2499105	20031003
EP 1554273	A1	20050720	EP 2003-807940	20031003

L12 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
BR 2003015206 A 20050816 BR 2003-15206 20031003  
US 2005070580 A1 20050331 US 2004-497626 20040603  
PRIORITY APPLN. INFO.: US 2002-417492P P 20021010  
WO 2003-IB4380 W 20031003

OTHER SOURCE(S): MARPAT 140:339319  
IT 680614-95-3P 680614-96-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of oxopyridinylphenyl oxazolidinones as antibacterial agents)  
RN 680614-95-3 HCAPLUS  
CN 4 (1H)-Pyridinone, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 680614-96-4 HCAPLUS  
CN 4 (1H)-Pyridinone, 2,3-dihydro-1-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
 ED Entered STN: 09 Apr 2004  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention provides a family of bifunctional heterocyclic compounds, e.g., I [A = C, C(O), N (with proviso, that at least one A = C); B = O, NR2, S(O), C(O), C(S), C(NOR3); p = 0, 1; q = 0, 1; r = 0 - 2; R2 = H, S(O)R4, CHO, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR2R2 = 5 to 8-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R3 = H, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 7-membered heterocycle (containing one or more N, S, O); NR3R3 = 5 to (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NHCOR3, C(O)NR3R3, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, etc.; D = O1, O2, O3, D4; E = di- or penta-substituted Ph, substituted 4-vinylphenyl; G = C1-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C,N,O,S; dashed line = single or double bond] or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional heterocyclic compounds, and methods of using such compounds as anti-infective, antiproliferative, anti-inflammatory and/or prokinetic agents. Thus, erythromycin derivative II was prepared from N-(desmethylerythromycin), via N-alkylation with HC.tplbond.CCH2CH2OTf, and cycloaddn. with azide III.


ACCESSION NUMBER: 2004:292029 HCAPLUS  
 DOCUMENT NUMBER: 140:321158  
 TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents  
 INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelare, Adegboyega K.; McConnell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.  
 PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 363 pp.  
 CODEN: P1XXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030925
WO 2004029066	C1	20040513		
WO 2004029066	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,


L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 morpholinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B



PAGE 2-A




IT 677726-17-9P 677726-31-7P 677726-85-1P  
 677726-86-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation and hydrolysis of; preparation of bifunctional heterocyclic compounds for use as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents)  
 RN 677726-17-9 HCAPLUS  
 CN 1-Oxa-6-azacyclotetradecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, HT, IL, KE, NE, SN, TD, TG  
 US 2005197334 A1 20050908 US 2003-671326 20030925  
 CA 2500158 AA 20040408 CA 2003-2500158 20030926  
 EP 1543017 A2 20050622 EP 2003-170506 20030926  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRIORITY APPLN. INFO.: US 2002-414207P P 20020926  
 US 2003-448216P P 20030219  
 WO 2003-US30478 W 20030925

OTHER SOURCE(S): MARPAT 140:321158  
 IT 677726-23-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and N-alkylation by, of des(N-methyl)erythromycin; preparation of bifunctional heterocyclic compounds for use as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents)  
 RN 677726-23-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-(2-[[4-methylphenyl]sulfonyl]oxy)ethyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 677726-15-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation and N-dealkylation of; preparation of bifunctional heterocyclic compounds for use as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents)  
 RN 677726-15-7 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[2-[1-[[5R]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)


L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[5R]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xyllo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677726-31-7 HCAPLUS  
 CN 1-Oxa-6-azacyclotetradecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[5R]-3-[3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xyllo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-85-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methyldino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-86-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methyldino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




IT 677726-19-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and tosylation of; preparation of bifunctional heterocyclic compds.

for use as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents)

RN 677726-19-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-(2-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 677726-37-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation and tosylation of; preparation of bifunctional heterocyclic compds.

for use as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents)

RN 677726-37-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-(2-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 677726-11-3P 677726-12-4P 677726-13-5P  
 677726-14-6P 677726-16-8P 677726-18-0P  
 677726-26-0P 677726-27-1P 677726-28-2P  
 677726-29-3P 677726-30-6P 677726-33-9P  
 677726-34-0P 677726-35-1P 677726-36-2P  
 677726-46-4P 677726-47-5P 677726-48-6P  
 677726-49-7P 677726-50-0P 677726-51-1P  
 677726-52-2P 677726-53-3P 677726-54-4P  
 677726-55-5P 677726-57-7P 677726-58-8P

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

677726-60-2P 677726-62-4P 677726-63-5P  
 677726-65-7P 677726-66-8P 677726-68-0P  
 677726-70-4P 677726-72-6P 677726-73-7P  
 677726-74-8P 677726-75-9P 677726-76-0P  
 677726-77-1P 677726-78-2P 677726-79-3P  
 677726-80-6P 677726-81-7P 677726-82-8P  
 677726-83-9P 677726-84-0P 677726-87-3P  
 677726-88-4P 677726-89-5P 677726-90-6P  
 677727-77-4P 677727-78-5P 677727-79-6P  
 677727-80-9P 677727-81-0P 677727-82-1P  
 677727-83-2P 677727-84-3P 677727-85-4P  
 677727-86-5P 677727-87-6P 677727-88-7P  
 677727-89-8P 677727-90-1P 677727-91-2P  
 677727-92-3P 677727-93-4P 677727-94-5P  
 677727-95-6P 677727-96-7P 677727-97-8P  
 677727-98-9P 677727-99-0P 677728-00-6P  
 677728-01-7P 677728-02-8P 677728-03-9P  
 677728-04-0P 677728-62-9P 678182-71-3DP,  
 trans-cyclohexanol isomers  
 RI: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (prepn. of bifunctional heterocyclic compds. for use as antiinfective,  
 antiproliferative, antiinflammatory and prokinetic agents)  
 RN 677726-11-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[[2-(2-  
 hydroxyethyl)methylamino]ethyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677726-12-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[2-[(2-  
 hydroxyethyl)methylamino]ethyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 677726-16-8 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[3-[1-[[5R]-3-[3-fluoro-4-(4-  
 morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-  
 yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 677726-13-5 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[[2-(2-  
 hydroxyethyl)methylamino]propyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677726-14-6 HCAPLUS

CN D-xyllo-Hexose, 3,4,6-trideoxy-3-[[[1-[[5R]-3-[3-fluoro-4-(4-  
 morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-  
 yl]methyl]methylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A




RN 677726-18-0 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 e-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[1-[[5R]-3-[3-  
 fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-  
 triazol-4-yl]propyl]methylamino]-p-D-xyllo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 677726-26-0 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677726-27-1 HCAPLUS  
CN Erythromycin, N-[2-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 677726-28-2 HCAPLUS  
CN Erythromycin, N-[3-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

Ac




PAGE 2-A

RN 677726-29-3 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 677726-30-6 HCAPLUS  
CN Erythromycin, N-demethyl-N-[2-[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 677726-33-9 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[2-[1-[[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 677726-35-1 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[2-[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 677726-34-0 HCAPLUS  
 CN Erythromycin, N-[2-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 677726-36-2 HCAPLUS  
 CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-N-demethyl-N-[2-[1-[[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-46-4 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[{(5R)-3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-48-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[{(5R)-3-[3-fluoro-4'-(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-B



RN 677726-47-5 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[{(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




RN 677726-49-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[{(5R)-3-[4-[[2-(acetoxyethyl)methylamino]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy- $\beta$ -D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-50-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[{(5R)-3-[4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-51-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[methyl[2-[1-[[[5R]-2-oxo-3-(3-pyridinyl)-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 677726-53-3 HCAPLUS  
 CN Erythromycin, 3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)-N-demethyl-N-[2-[1-[[[5R]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-52-2 HCAPLUS  
 CN Erythromycin, N,N-didemethyl-N-[2-[1-[[[5R]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 677726-54-4 HCAPLUS  
 CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-N-demethyl-N-[2-[1-[[[5R]-3-[3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 677726-55-5 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-58-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[2-[1-[[[(5R)-3-(4'-cyano-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-57-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-60-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 677726-62-4 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-[[4-[[dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677726-63-5 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[[(5R)-3-(4-cyano-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-3,4,6-trideoxy- $\beta$ -D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-,

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-66-8 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[methyl(2-[1-[[[(5R)-3-[4-[[[(methylsulfonyl)amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677726-65-7 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-68-0 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[[(5R)-3-[3-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-3,4,6-trideoxy- $\beta$ -D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-70-4 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[[2-[1-[[[(5R)-3-[4-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-72-6 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-[[[(dimethylamino)methylene]amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-73-7 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[[2-[1-[[[(5R)-3-[4-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-74-8 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-[[[(dimethylamino)methylene]amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-75-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[[2-[1-[[[(5R)-3-(1,3-benzodioxol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-76-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[methyl[2-[1-[[[(5R)-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




PAGE 2-B


RN 677726-77-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[methyl[2-[1-[[[(5R)-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 677726-78-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxyl]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxyl]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-79-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxyl]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxyl]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-80-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxyl]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[4-[1-[[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxyl]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 677726-81-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxyl]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B




RN 677726-82-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[4-[[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-83-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[3-[[1-[[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 677726-87-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 triazol-4-yl]-1-propenyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 677726-84-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[3-[[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-propenyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B




RN 677726-88-4 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[[1-[[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-89-5 HCAPLUS  
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[[3,4,6-trideoxy-3-[[[2-[[1-[[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B


RN 677726-90-8 HCAPLUS  
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



PAGE 1-A




PAGE 1-B

RN 677727-78-5 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[3-[1-[[[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-77-4 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-79-6 HCAPLUS  
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[3-[1-[[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-80-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-81-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-82-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 677727-83-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-84-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(2-  
 fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-85-4 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(3-  
 fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-86-5 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-(4-  
 fluoro-3-methylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677727-87-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-  
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-  
 3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[(5R)-3-[4-(3-  
 hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-  
 yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B




RN 677727-88-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-[4-(2-hydroxyethyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-89-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-90-1 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-91-2 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[[1-[[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-92-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[[[(SR)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-93-4 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[[[(SR)-3-(2-fluoro-4'-[(4-quinolinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-94-5 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[[[(SR)-3-(3-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677727-95-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[[1-[[[(SR)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-96-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethoxy]carbonyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-97-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethoxy]carbonyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-98-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[(5R)-3-[4-[(dimethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 677727-99-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[[2-[1-[(5R)-3-[4-[(dimethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- $\beta$ -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-00-6 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[2-[[1-[[[(5R)-3-(3-chloro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-01-7 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[[3-[[2-[[1-[[[(5R)-3-(3-chloro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-02-8 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[methyl[2-[[1-[[[(5R)-2-oxo-3-(4-(trifluoromethoxy)phenyl]-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-03-9 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[methyl[2-[[1-[[[(5R)-2-oxo-3-(4-(trifluoromethoxy)phenyl]-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-04-0 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[5R]-3-(3-fluoro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677729-42-9 HCAPLUS  
 CN Erythromycin, N-demethyl-N-[2-[1-[[[5R]-3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 678182-71-3 HCAPLUS  
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[5R]-3-(trans-4-hydroxycyclohexyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 648919-12-4 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 648919-01-6P 648919-11-3P 648920-06-3P  
 648920-10-9P 648920-11-0P 648920-33-6P  
 648920-34-7P 648920-35-8P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 648920-06-3 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[[(5R)-3-[4-[4-(cyanomethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (prepn. of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)

RN 648918-91-6 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648919-11-3 HCAPLUS  
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 648920-10-9 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[[(5R)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648920-11-0 HCAPLUS  
 CN 4-Piperidineacetonitrile, 1-[[[(5R)-5-[(4-cyano-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 648920-33-6 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648920-34-7 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



IT 648921-31-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)  
 RN 648921-31-7 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 648921-09-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)  
 RN 648921-09-9 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 648920-35-8 HCAPLUS  
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[[[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)





L12 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
ED Entered STN: 28 Nov 2003  
GI



AB The title compds. [I: R1-R5 = H, halo, (un)substituted alkoxy, F, Q = halo, OH, NH2, N3, each (un)substituted C1-8 alkoxy, C1-8 alkanyloxy, C1-8 alkylsulfonyl, C1-8 alkylsulfonylethoxy, mono- or di(C1-8 alkyl)amino, C1-8 alkanylamino, C3-8 cycloalkenylcarbonylamino, monocyclic (un)saturated heterocyclylcarbonylamino, C1-8 alkylcarbonylamino, tri(C1-8 alkyl)silyloxy, or N-C1-8 alkyl-N-C1-8 alkylcarbonylamino] or pharmacol. acceptable salts thereof or hydrates thereof are prepared. These compds. I possess antibacterial activity against sensitive bacteria on which existing drugs are effective as well as multidrug-resistant bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), and Penicillin-resistant *Streptococcus pneumoniae* (PRSP). Thus, 7.5 µL Et dithioacetate was added to a solution of 15.1 mg 4-[(5S)-5-acetamidomethyl-2-oxazolidin-3-yl]-4'-[(5S)-5-aminomethyl-2-oxazolidin-3-yl]-2,2'-difluorobiphenyl (preparation given) in 0.5 mL DMF and stirred at room temperature for 14 h to give 80% 4-[(5S)-5-acetamidomethyl-2-oxazolidin-3-yl]-4'-[(5S)-5-thioacetamidomethyl-2-oxazolidin-3-yl]-2,2'-difluorobiphenyl (II). II showed min. inhibitory concentration of 0.125 µg/mL against MRSA and vancomycin-resistant *Enterococcus faecium*.


ACCESSION NUMBER: 2003:929541 HCAPLUS  
DOCUMENT NUMBER: 140:5040  
TITLE: Preparation of bis(2-oxazolidin-3-yl)biphenyl derivatives as antibacterial agents  
INVENTOR(S): Shiohara, Sojiro; Ishikawa, Makoto; Yanagisawa, Yukio; Kawaguchi, Masami; Maehashi, Kazunori; Yoshida, Satoshi  
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.  
CODEN: JKKOAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003335762	A2	20031128	JP 2002-144414	20020520
PRIORITY APPL. INFO.:			JP 2002-144414	20020520

OTHER SOURCE(S): MARPAT 140:5040

IT 627542-99-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
ED Entered STN: 05 Sep 2003  
GI




AB 3-Cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-azidomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is, for example, halo or (1-4C)alkyl that is substituted by 1 substituent -, for example, OH, (1-4C)alkoxy, amino, cyano, azido, Q = for example, 3-R2-4-T-5-R3phenyl wherein R2 and R3 = H or fluoro; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to 5) are useful as antibacterial agents and processes for their manufacture and pharmaceutical compns. containing them are described. Compds. I have a good spectrum of activity in vitro against standard organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive *Staphylococcus aureus* and against methicillin resistant and quinolone resistant *Staphylococcus aureus* are 4 and 8 µg/mL, resp. Compds. I showed a favorable decreased MAC-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azidomethyl or hydroxymethyl. They also showed favorable decreased MAC-A potency compared with analogs in which the HET group is unsubstituted. Sixty-one example preps. of I are included. For example, to prepare II, (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (2.7 mmol) (preparation given) was suspended in CH2Cl2 (10 mL), 1,8-diazabicyclo[5.4.0]undec-7-ene (4.7 mmol) was added and the reaction mixture was cooled to -5°C; diphenylphosphoryl azide (3.25 mmol) was added dropwise and it was stirred for 18 h at room temperature; workup gave 1.02 g of II.

ACCESSION NUMBER: 2003:696895 HCAPLUS  
DOCUMENT NUMBER: 139:214459  
TITLE: Preparation of 5-azolylmethyl oxazolidinones and their use as antibacterial agents  
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague, Daniel Robert  
PATENT ASSIGNEE(S): AstraZeneca AB, Sued., AstraZeneca UK Limited  
SOURCE: PCT Int. Appl., 126 pp.


L12 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
(Uses)  
(prepn. of bisoxazolidinyl)biphenyl derivs. as antibacterial agents)  
RN 627542-99-8 HCAPLUS  
CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-yl]-(5S)-2-oxo-5-(1H-1,2,3-triazol-1-yl)methyl-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 627543-24-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of bisoxazolidinyl)biphenyl derivs. as antibacterial agents)  
RN 627543-24-2 HCAPLUS  
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072576	A2	20030904	WO 2003-GB791	20030225
WO 2003072576	A3	20031231		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477379	AA	20030904	CA 2003-2477379	20030225
EP 1480975	A2	20041201	EP 2003-742987	20030225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 200308018	A	20050104	BR 2003-8018	20030225
US 200518212	A1	20050818	US 2003-505902	20030225
JP 2005531504	T2	20051020	JP 2003-571282	20030225
PRIORITY APPL. INFO.:			US 2002-360688P	P 20020228
			WO 2003-GB791	W 20030225

OTHER SOURCE(S): MARPAT 139:214459  
IT 591253-17-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(methoxycarbonyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-18-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-azidomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-19-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-20-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-aminomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-21-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-bromomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-22-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-iodomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-23-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-24-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-25-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-propylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-26-6P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-isopropylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-27-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-tert-butylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-28-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-phenylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-29-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-30-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-31-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-32-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-33-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-34-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-35-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-36-6P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-37-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-38-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-39-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-40-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-41-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-42-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-43-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-44-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-45-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-46-6P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-47-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-48-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-49-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-50-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-51-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-52-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-53-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-54-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-55-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-56-6P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-57-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-58-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-59-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-60-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-61-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-62-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-63-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-64-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-65-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-66-6P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-67-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-68-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-69-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-70-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-71-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-72-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-73-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-74-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-75-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-76-6P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-77-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-78-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-79-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-80-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-81-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-82-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-83-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-84-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-85-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-86-6P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-87-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-88-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-89-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-90-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-91-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-92-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-93-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-94-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-95-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-96-6P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-97-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-98-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-99-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-100-0P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-101-1P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-methylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-102-2P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-ethylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-103-3P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-isopropylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-104-4P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(4-tert-butylphenylthio)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-105-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluoroph

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (2-propynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one  
 591253-98-4P, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 591254-03-4P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(2-hydroxyethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; prepn. of 5-azolylmethyl oxazolidinones and their use as antibacterial agents)  
 RN 591253-17-7 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[[(5R)-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-18-8 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(azidomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-19-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-23-5 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-26-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-27-9 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(bromomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-30-4 HCAPLUS  
 CN Carbamimidothioic acid, [1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methyl ester, monohydrobromide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-31-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(methylthio)methyl]-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-34-8 HCAPLUS  
 CN Phosphoric acid, 1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]-1H-1,2,3-triazol-4-yl]methyl diphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-50-8 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]-1H-1,2,3-triazol-4-yl]methyl diphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-54-2 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(2,2-dibromoethenyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-69-9 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(2,2-dibromoethenyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-75-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(2-ethoxy-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-77-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(2-ethoxy-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-84-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(2-propynyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-98-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(2-propynyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 591254-03-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxo-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 591253-16-6P, (SR)-3-[[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-hydroxymethyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-21-3P, (SR)-3-[[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-trifluoromethyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-24-6P, (SR)-3-[[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(aminocarbonyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-25-7P, (SR)-3-[[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[methoxycarbonyl]amino]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-28-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-fluoromethyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-32-6P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[methylsulfonyl]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

591253-91-7P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(2,5-dihydro-1H-pyrazol-1-yl)-2-butynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-92-8P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[morpholinyl]-2-butynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-93-9P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[morpholinyl]-2-butynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one trifluoroacetate 591253-94-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-ethynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-96-2P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-hydroxy-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-97-3P, (SR)-3-[[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591254-00-1P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(4-methylthio-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591254-01-2P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(4-cyclopropyl-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591254-04-5P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-ethynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591254-05-6P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(methoxymethyl)-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one 591254-06-7P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[5-(methoxymethyl)-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one 591254-07-8P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(4-chloromethyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591254-08-9P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-ethynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591254-09-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-[[[1,1-dimethylethoxy]carbonyl]amino]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591254-10-3P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(2-chloroethyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591254-11-4P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(4-nitro-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Drug candidate) prepn. of 5-azolylmethyl oxazolidinones and their use as antibacterial agents)

RN 591253-16-6 HCAPLUS


CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[5-[[3-[[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)


591253-36-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-cyanomethyl-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-38-2P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-chloromethyl-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-40-6P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-hydroxymethyl-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-42-8P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[1H-1,2,3-triazol-4-yl]thio]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-44-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[1H-imidazol-2-yl]thio]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-46-2P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[phenylmethyl]thio]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-48-4P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[dimethylamino]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-52-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-difluoromethyl-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-56-4P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[2-(3-methyl-5-oxazoyl)ethynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-58-6P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[3-buten-1-ynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-60-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[2-bromoethyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-62-2P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[2-(2-bromoethyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-64-4P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[2-[[[ethyl]amino]-2-oxoethyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-68-5P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[2-(dimethylamino)-2-oxoethyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-67-7P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[[ethylaminocarbonyloxy]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-74-6P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-acetylamin-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-78-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-chloro-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-81-8P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-fluoro-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-82-6P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-fluoro-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-83-7P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[3-hydroxy-1-propynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-86-0P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[4-(dimethylamino-2-butynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-87-8P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[4-(dimethylamino-2-butynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one trifluoroacetate 591253-88-2P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(5-hydroxymethyl-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-89-3P, (SR)-3-[[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[4-(diethylamino-2-butynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one trifluoroacetate

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 591253-20-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-21-3 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-22-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-24-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-((methylsulfonyl)methyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-32-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-((methylsulfonyl)methyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-36-0 HCAPLUS  
CN 1H-1,2,3-Triazole-4-acetonitrile, 1-[[[(5R)-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-25-7 HCAPLUS  
CN Carbamic acid, [[1-[[[(5R)-3-[[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-28-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-((fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-38-2 HCAPLUS  
CN 2-Oxazolidinone, 5-[[4-(chloromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-40-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-42-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-((3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)]-5-[[4-((1H-1,2,3-triazol-4-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-44-0 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-((3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)]-5-[[4-((1H-imidazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-52-0 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-((difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl)-3-((3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-56-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-((3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)]-5-[[4-((3-methyl-5-isoxazolyl)ethynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-46-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-((3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)]-5-[[4-((phenylmethyl)thio)methyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-48-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-((3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)]-5-[[4-((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-58-6 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-((3-buten-1-ynyl)-1H-1,2,3-triazol-1-yl)methyl)-3-((3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-60-0 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-((1E)-2-bromoethenyl)-1H-1,2,3-triazol-1-yl)methyl)-3-((3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)]-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-62-2 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(bromoethynyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-64-4 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-acetamide, 1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-74-6 HCAPLUS  
 CN Acetamide, N-[1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-78-0 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-65-5 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-acetamide, 1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-67-7 HCAPLUS  
 CN Carbamic acid, ethyl-, [1-[[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-81-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-82-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-83-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(3-hydroxy-1-propynyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-86-0 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-(dimethylamino)-2-butynyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 591253-88-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-89-3 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(4-(diethylamino)-2-butynyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 591253-87-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-(dimethylamino)-2-butynyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 591253-86-0  
 CMF C23 H26 F N5 O4 S

Absolute stereochemistry.



CH 2

CRN 76-05-1  
 CMF C2 H F3 O2


L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 591253-90-6 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(4-(diethylamino)-2-butynyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 591253-89-3  
 CMF C25 H30 F N5 O4 S

Absolute stereochemistry.



CH 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 591253-91-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-(2,5-dihydro-1H-pyrrol-1-yl)-2-butynyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-92-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(4-morpholinyl)-2-butynyl]-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-93-9 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(4-morpholinyl)-2-butynyl]-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 591253-92-8  
CMF C25 H28 F NS O5 S


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-96-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxy-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-97-3 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 591253-94-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(4-methylthio-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-00-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-[(4-methylthio-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591254-01-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-[(4-methylthio-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-04-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-ethynyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 591254-05-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(methoxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-08-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-ethynyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 591254-09-0 HCAPLUS  
 CN Carbanic acid, [[1-[[[5R]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-06-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[5-(methoxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 591254-07-8 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(chloromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-, (5R)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-10-3 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[4-(2-chloroethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-, (5R)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-11-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(nitro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

(Continued)




IT 591253-71-3P, (5R)-3-[[4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-carboxy-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-85-9P, (5R)-3-[[4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(3-(trimethylsilyl)-2-propynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-98-1P, (5R)-3-[[4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(2-(trimethylsilyl)ethynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 5-azolymethyl oxazolidinones and their use as antibacterial agents)

RN 591253-71-3 HCAPLUS

CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[5R]-3-[[4-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 05 Sep 2003

GI



AB 3-Cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[[4-[(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is (1-4C)alkyl; Q = for example, 3-R2-4-R3-phenyl wherein R2 and R3 = H or fluorine; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to S), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, are useful as antibacterial agents and processes for their manufacture and pharmaceutical compns. containing them are described. Compds. I have a good spectrum of activity in vitro against standard organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive *Staphylococcus aureus* and against methicillin resistant and quinolone resistant *Staphylococcus aureus* are 2 and 4 µg/mL, resp., compared to 2 and 2 µg/mL for the reference compound without the Me substituent. Compds. I showed a favorable decreased MAO-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azolymethyl or hydroxymethyl. They also showed favorable decreased MAO-A potency compared with analogs in which the HET group is unsubstituted. Fifty-seven example preps. of intermediates and 44 example preps. of I are included. For example, to prepare II, (5R)-3-[[4-[(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-azidomethyl]oxazolidin-2-one (1.0 mmol; preparation described) was mixed with 5,6,7,8-tetrachloro-2,9-dimethyl-1,4-dihydro-1,4-ethenonaphthalene (2.0 mmol) in dry 1,4-dioxane (4 mL) in a sealed microwave reaction tube. The tube was placed in a Smith microwave reactor at 170° for 20 min. The reaction mixture was then transferred into a round bottom flask and the solvent was removed under vacuum. The residue was purified by chromatog. on silica gel with 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to give a mixture of the 4- and 5-Me regioisomers. This mixture was further separated on a chiral column (chiralcel OD) with iso-PrOH/hexanes (1:1) to give II (74 mg).

ACCESSION NUMBER: 2003:696894 HCAPLUS

DOCUMENT NUMBER: 139:214458

TITLE: Preparation of 3-cyclyl-5-[(nitrogen-containing


L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

RN 591253-85-9 HCAPLUS

CN 2-Oxazolidinone, 3-[[4-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(3-(trimethylsilyl)-2-propynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-95-1 HCAPLUS

CN 2-Oxazolidinone, 3-[[4-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(3-(trimethylsilyl)ethynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

5-membered ring)methyl]oxazolidinones and their use as

antibacterial agents

INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Rack,

Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague,

Daniel Robert; Girardot, Marc Michel

Astrazeneca AB, Swed.; Astrazeneca UK Limited

PATENT ASSIGNEE(S): PCT Int. Appl., 140 pp.

SOURCE: CODEN: PINX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072575	A1	20030904	WO 2003-GB785	20030225
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GR, GM, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, HT, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
CA 2477344	AA	20030904	CA 2003-2477344	20030225
BR 2003008056	A	20041207	BR 2003-8056	20030225
EP 1497286	A1	20050119	EP 2003-704812	20030225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005119292	A1	20050602	US 2003-506020	20030225
JP 2005524661	T2	20050818	JP 2003-571281	20030225
NO 200403950	A	20041013	NO 2004-3950	20040921
PRIORITY APPL. INFO.:			US 2002-360957P	P 20020228
			WO 2003-GB785	W 20030225

OTHER SOURCE(S): MARPAT 139:214458


IT 591232-01-8P, (5R)-3-[[3-Fluoro-4-[(1-oxo-4-thiomorpholinyl)phenyl]-5-[[4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-62-1P, (5R)-3-[[4-(Tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-91-6P, (5R)-3-[[4-[(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[[4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-96-1P, (5R)-3-[[4-[(Acetoxymethyl)-1,2,3,6-tetrahydropyridin-4-yl]-3-fluorophenyl]-5-[[4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidates: preparation of cyclyl (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591232-01-8 HCAPLUS

CN 2-Oxazolidinone, 3-[[3-fluoro-4-[(1-oxido-4-thiomorpholinyl)phenyl]-5-[[4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 591232-62-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,5-difluoro-4-[(tetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 591232-91-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[(3,5-difluoro-4-[(1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
one 591231-95-7P, (5R)-3-[4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-97-9P, (5R)-3-[4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-00-7P, (5R)-3-[4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-02-9P, (5R)-3-[4-[(1,1-Dioxo-4-thiomorpholinyl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-03-0P, (5R)-3-[3,5-Difluoro-4-(1-oxo-4-thiomorpholinyl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-09-6P, (5R)-3-[4-[(1,1-Dioxo-4-thiomorpholinyl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-11-0P, (5R)-3-[4-[(1,1-Dioxotetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-12-1P, (5R)-3-[4-[(1,1-Dioxo-2,5-dihydrothien-3-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-13-2P, (5R)-3-[3-Fluoro-4-(4-bromo-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-15-4P, (5R)-3-[3-Fluoro-4-(4-methyl-1,2,3-triazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-23-4P, (5R)-3-[3-Fluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-31-4P, (5R)-3-[3-Fluoro-4-[4-[(hydroxymethyl)methyl]imidazol-1-yl]phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-42-7P, (5R)-3-[3-Fluoro-4-(4-formylimidazol-1-yl)phenyl]-5-[(4-pentyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-43-8P, (5R)-3-[3-Fluoro-4-(4-(hydroxymethyl)-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-46-1P, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-49-4P, (5R)-3-[3-Fluoro-4-(1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-50-7P, (5R)-3-[3-Fluoro-4-(4-cyano-1H-pyrazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-58-5P, (5R)-3-[3-Fluoro-4-(trans-1-oxotetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-60-9P, (5R)-3-[3-Fluoro-4-(cis-1-oxotetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 591232-68-7P, (5R)-3-[4-[(1,1-Dioxotetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-69-8P, (5R)-3-[3,5-Difluoro-4-(trans-1-oxotetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-70-1P, (5R)-3-[3,5-Difluoro-4-(cis-1-oxotetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-88-1P, (5R)-3-[3,5-Difluoro-4-(1-glycolyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-93-8P, (5R)-3-[4-[(1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-95-0P, (5R)-3-[3-Fluoro-4-(1-glycolyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; prepn. of cyclyl (nitrogen-contg. 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)


RN 591231-77-5 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)]

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 591232-96-1 HCAPLUS  
CN Pyridine, 1-[(acetyloxy)acetyl]-4-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



IT 591231-77-5P, (5R)-3-[4-[(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-84-4P, (5R)-3-[4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-90-2P, (5R)-3-[4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-


L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

Absolute stereochemistry.



RN 591231-84-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 591231-90-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591231-95-7 HCAPLUS  
CN 2-Oxazolidinone, 5-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 591231-97-9 HCAPLUS  
CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-ethyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-03-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 591232-09-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-00-7 HCAPLUS  
CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-ethyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 591232-02-9 HCAPLUS  
CN 2-Oxazolidinone, 3-[(4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-11-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 591232-12-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-(2,5-dihydro-1,1-dioxido-3-thienyl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 591232-13-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-15-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-23-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 591232-46-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-49-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-50-7 HCAPLUS  
CN 1H-Pyrazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 591232-31-4 HCAPLUS  
CN 1H-Imidazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, 4-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 591232-42-7 HCAPLUS  
CN 1H-Imidazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-[(4-pentyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-43-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-(hydroxymethyl)-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-58-5 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-60-9 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-68-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-((tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)methyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-69-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-((trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)methyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-93-8 HCAPLUS  
 CN Pyridine, 4-[[2,6-difluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-95-0 HCAPLUS  
 CN Pyridine, 4-[[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-70-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-((cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)methyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-88-1 HCAPLUS  
 CN Pyridine, 4-[[2,6-difluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 591232-98-3P, (5R)-3-[(4-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 RL; PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (Preparation of cyclol (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591232-98-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-98-6P, (5R)-3-[(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 501940-28-9P,


L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (SR)-3-(3-Fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 591232-44-9P, (SR)-3-[4-[(tert-Butyldimethylsilyloxy)methyl]-1H-imidazol-1-yl]-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-89-2P, (SR)-3-[4-(1-Acetoxyacetyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-90-5P, (SR)-3-[3,5-Difluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one hydrochloride 591232-94-9P, (SR)-3-[4-{1-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]carbonyl}-1,2,3,6-tetrahydropyridin-4-yl]-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-97-2P, (SR)-3-[3-Fluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one monohydrochloride  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of cyclyl (nitrogen-contg. 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)  
 RN 501939-98-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-28-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-94-9 HCAPLUS  
 CN Pyridine, 4-[2,6-difluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-97-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, monohydrochloride, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 591232-44-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-1H-imidazol-1-yl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-89-2 HCAPLUS  
 CN Pyridine, 1-[(acetyloxy)acetyl]-4-[2,6-difluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-90-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, hydrochloride, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 591231-82-2P, (SR)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of cyclyl (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)  
 RN 591231-82-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 29 Jul 2003  
 GI



AB Title compds. 1 (R1 = H, halo, alkyl, or haloalkyl; R2 = morpholinyl, piperidinyl or its derivative, or 4-substituted piperazinyl; R3 = OH, SH, acyloxy, sulfonyloxy, acylamino, diacylimino, pentabasic heterocyclic group or its deriv.; and when R1 = F, R2 or R3 = morpholinyl or acetamido), useful as antibacterial agents against Gram-pos. bacteria, are prepared. For example, (R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(hydroxymethyl)-2-oxazolidinone was converted to mesylate, condensed with potassium phthalimide, and treated with aqueous MeNH2 to give the bactericide linezolid.


ACCESSION NUMBER: 2003:576097 HCAPLUS  
 DOCUMENT NUMBER: 139:85332  
 TITLE: Preparation of oxazolidone derivatives as antibacterial agents  
 INVENTOR(S): Liu, Jun; Meng, Qingguo; Jin, Jie; Wu, Yanbin  
 PATENT ASSIGNER(S): Institute of Medical and Biological Technology, Chinese Academy of Medical Sciences, Peop. Rep. China  
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 50 pp.  
 CODEN: CMOXEV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1355165	A	20020626	CN 2001-144613	20011219
			CN 2001-144613	20011219

PRIORITY APPL. INFO.: CASREACT 139:85332; MARPAT 139:85332  
 OTHER SOURCE(S):  
 IT 556801-07-1P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of oxazolidone derivs. as antibacterial agents)  
 RN 556801-07-1 HCAPLUS  
 CN 2-Oxazolidinone, 5-(1H-benzotriazol-1-ylmethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L12 ANSWER 34 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN


ED Entered STN: 20 Jun 2003

AB PH-027 is a new 5-triazole oxazolidinone synthesized that shows strong activity against Gram-pos. aerobic bacteria, including clin. isolates. The objective of this study was to investigate the in vitro activity of this compound in comparison with linezolid and other antibiotics against Gram-pos. and Gram-neg. anaerobes. The in vitro activity of PH-027 in comparison with those of linezolid and other antimicrobial agents was evaluated against 201 clin. isolates of Gram-pos. and Gram-neg. anaerobic bacteria by agar dilution and Etest methods. PH-027 showed excellent activity, with min. inhibitory concns. (MIC) in the range of 0.12-4.0 µg/mL against all isolates; MIC90s being 4.0, 1.0, 2.0, 2.0 and 2.0 µg/mL against Clostridium difficile, Peptostreptococcus spp., Bacteroides fragilis, Prevotella bivia and Fusobacterium spp. resp. In comparison, linezolid had MIC in the range of 0.5-4.0 µg/mL against all isolates, with MIC90s of 2.0, 4.0, 4.0, 4.0 and 2.0 µg/mL against the same set of bacteria resp. PH-027 demonstrated excellent in vitro activity that is superior to linezolid against Peptostreptococcus spp., B. fragilis and P. bivia. However, against C. difficile and Fusobacterium spp. PH-027 and linezolid showed comparable in vitro activity. Against all anaerobes, metronidazole, PH-027 and, to a lesser extent, linezolid had the most potent activity. From the results of in vitro susceptibility testing, both linezolid and PH-027 show promise in the treatment of anaerobic infections.

ACCESSION NUMBER: 2003:471767 HCAPLUS  
 DOCUMENT NUMBER: 139:49714  
 TITLE: Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria  
 AUTHOR(S): Phillips, O. A.; Rotimi, V. O.; Jamal, W. Y.; Shahin, M.; Verghese, T. L.  
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Kuwait  
 SOURCE: Journal of Chemotherapy (Firenze, Italy) (2003), 15(2), 113-117  
 CODEN: JCHKEU; ISSN: 1120-009X  
 PUBLISHER: E.I.F.T. srl  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 503090-32-2, PH 027  
 RI: BSU (Biological study, unclassified); BIOL (Biological study) (comparative in vitro activity of PH-027 vs. other antimicrobials against clin. isolates of Clostridium difficile and other anaerobic bacteria)  
 RN 503090-32-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 34 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
ED Entered STN: 13 Jun 2003  
GI



AB Title compds. [1: R1 = H, NR5R6, CR7R8R9, CR2OR14, CH2NHR14, COR13, C(:NOH)H, C(:NOR13)H, C(:NOR13)R13, C(:NOH)R13, COW(R13)2, C(:NOH)N(R13)2, NHC(:X1)N(R13)2, C(:NH)R7, N(R13)C(:X1)N(R13)2, CO2R13, SO2R14, N(R13)SO2R14, N(R13)COR14, cyanoalkyl, CN, CH3C(R)2, CH, COCHER13, C(:NR13)R13, NHC(:X1)R13, (substituted) heterocycle; Ar = (substituted) aryl, heteroaryl, heterocyclyl; R3 = NR13(C:X2)R12, NR13(C:X1)R12, NR13SO2R14, NR13(CHR13)0-4aryl, NR13(CHR13)0-4heteroaryl, S(CHR13)0-4aryl, S(CHR13)0-4heteroaryl, O(CHR13)0-4aryl, O(CHR13)0-4heteroaryl; OC(R13)NR16, (substituted) heterocyclyl; R5, R6 = H, (substituted) alkyl, acyl, heterocyclyl; R5R6 = atoms to form 3-7 membered heterocyclyl; R7 = H, halo, OR, alkoxy, alkyl, alkenyl, (substituted) amino; R8, R9 = H, cyano, (substituted) alkyl, Ph; R7R8 = atoms to form a 3-7 membered (heterocyclyl) ring; X1 = O, S, NR13, NCM, NSO2R14; R13 = H, alkyl, NR5R6, SR8, OH, cyano, etc.; R14 = amino, alkyl, haloalkyl, (substituted) heterocyclyl, Ph, were prepared. Thus, N-[5(S)-3-[4-(1-cyanocyclopropan-1-yl)-3-fluorophenyl]-2-oxoxazolidin-5-ylmethyl]acetamide (preparation given) in PhMe was treated with Lawesson's reagent and stirred at 80° for 2 h to give N-[5(S)-3-[4-(1-cyanocyclopropan-1-yl)-3-fluorophenyl]-2-oxoxazolidin-5-ylmethyl]thioacetamide. The latter inhibited *Staphylococcus aureus* Smith with a min. inhibitory concentration of 0.125 µg/mL.


ACCESSION NUMBER: 2003:454302 HCAPLUS  
DOCUMENT NUMBER: 139:36518  
TITLE: Preparation of chiral cyclopropylphenylloxazolidinones as antibiotics  
INVENTOR(S): Fukuda, Yasumichi  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.  
SOURCE: PCT Int. Appl., 133 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048136	A1	20030612	WO 2002-US38153	20021127
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
CA 2463794 AA 20030612 CA 2002-2463794 20021127  
US 2003225107 A1 20031204 US 2002-305368 20021127  
US 6686363 B2 20040203  
EP 1448536 A1 20040825 EP 2002-797154 20021127  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, ER, SK  
JP 2005511688 T2 20050428 JP 2003-549328 20021127  
PRIORITY APPLN. INFO.: US 2001-333741P P 20011129  
WO 2002-US38153 W 20021127

OTHER SOURCE(S): MARPAT 139:36518  
IT 543682-63-9P 543682-75-3P 543682-78-6P  
R: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(Claimed compound: preparation of chiral cyclopropylphenylloxazolidinones as antibiotics)  
RN 543682-63-9 HCAPLUS  
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543682-75-3 HCAPLUS  
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-(azidomethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 543682-78-6 HCAPLUS  
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-[(methylsulfonyl)oxy]methyl]-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 543682-51-5P 543682-52-6P 543682-53-7P  
543682-54-6P 543682-55-9P 543682-56-0P  
543682-58-1P 543682-56-2P 543682-57-3P  
543682-60-4P 543682-69-5P 543682-70-6P  
543682-71-9P 543682-72-0P 543682-73-1P  
543682-74-2P 543682-76-4P 543682-77-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Claimed compound: preparation of chiral cyclopropylphenylloxazolidinones as antibiotics)  
RN 543682-51-5 HCAPLUS  
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 543682-52-6 HCAPLUS  
CN 1H-1,2,3-Triazole-4-carbonitrile, 5-amino-1-[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-53-7 HCAPLUS  
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 543682-54-8 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-55-9 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543682-64-0 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 543682-67-3 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-68-4 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-69-5 HCAPLUS

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-65-1 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-66-2 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-70-8 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(4-formyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543682-71-9 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(4-(hydroxyimino)methyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry unknown.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-72-0 HCAPLUS  
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[4-((5R)-3-[(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinylphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543682-73-1 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[[4-((5R)-5-[[4-[(methoxymethyl)methyl]-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-oxo-3-oxazolidinylphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry unknown.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-74-2 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[[4-((5R)-5-[[4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-oxo-3-oxazolidinylphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543682-76-4 HCAPLUS  
 CN Acetamide, N-[[1-[[4-((5R)-3-[(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-77-5 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[[4-((5R)-5-[[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-oxo-3-oxazolidinylphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 543683-57-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of chiral cyclopropylphenylloxazolidinones as antibiotics)  
 RN 543683-57-4 HCAPLUS  
 CN Cyclopropanecarbonitrile, 1-[[2-methyl-4-((5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]-2-oxo-3-oxazolidinylphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 02 May 2003  
 GI



AB Title compds. I [wherein HET = (un)substituted N-linked 5-membered heterocyclic or 6-membered dihydroheteroaryl ring containing heteroatoms selected from N, O, and S; Q = Q1, Q2, etc.; R2 and R3 = independently H or F; T = (un)substituted C-linked 5-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; preferably T = (un)substituted 1,3,4-thiadiazolyl, thiazolyl, 1,3,4-oxadiazolyl, or oxazolyl; and pharmaceutically acceptable salts or hydrolyzable esters thereof] were prepared as antibacterial agents. For example, (5R)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one was mesylated and the product converted to the azide. Cyclization of the azide with bicyclo[2.2.1]heptadiene gave the 1,2,3-triazole, which was substituted with hexamethylditin to afford the stannane. Reaction with 5-chloro-1,3,4-thiadiazole-2-carbonitrile in the presence of AsPh3 and tris(dibenzylideneacetone)dipalladium in N-methyl-2-pyrrolidinone provided II. The latter inhibited bacterial growth against *Staphylococcus aureus* (methicillin sensitive and quinolone sensitive), *Staphylococcus aureus* (methicillin resistant and quinolone resistant), *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Haemophilus influenzae*, and *Moraxella catarrhalis* with MIC values of 0.125 µg/mL, 0.25 µg/mL, 0.125 µg/mL, 0.125 µg/mL, 2 µg/mL, and 0.5 µg/mL, resp.


ACCESSION NUMBER: 2003:335104 HCAPLUS  
 DOCUMENT NUMBER: 138:353972  
 TITLE: Preparation of 3-aryloxazolidinones with antibacterial activity  
 INVENTOR(S): Gravestock, Michael Barry  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 80 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 519003-02-2 HCAPLUS  
 CN 1,3,4-thiadiazole-2-carboxylic acid, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-03-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[5-(aminomethyl)-2-thiazolyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-05-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[5-(aminomethyl)-2-thiazolyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035648	A1	20030501	WO 2002-GB4796	20021023
V:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
GB 2396350	A1	20040623	GB 2004-8399	20021023
EP 1446403	A1	20040818	EP 2002-770098	20021023
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005519870	T2	20050707	JP 2003-538164	20021023
US 2005043374	A1	20050224	US 2004-493609	20041018
PRIORITY APPLN. INFO.:			US 2001-330589P	P 20011025
			WO 2002-GB4796	W 20021023

OTHER SOURCE(S): MARPAT 138:353972  
 IT 519003-00-0P, (5R)-3-[3-fluoro-4-(5-cyano-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 519003-02-2P, (5R)-3-[3-fluoro-4-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 519003-03-3P, (5R)-3-[4-[5-(aminomethyl)-1,3-thiazol-2-yl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 519003-05-5P, (5R)-3-[3-fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 519003-11-3P, (5R)-3-[3-fluoro-4-(4-methyl-1,3-thiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 519003-14-6P, (5R)-3-[3-fluoro-4-(4-(trifluoromethyl)-1,3-thiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 519003-16-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (antibacterial agent; preparation of (aryl)oxazolidinones as antibacterial agents)  
 RN 519003-00-0 HCAPLUS  
 CN 1,3,4-thiadiazole-2-carbonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 519003-11-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-methyl-2-thiazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-14-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(trifluoromethyl)-2-thiazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 519003-16-8 HCAPLUS  
 CN 1,3,4-thiadiazole-2-acetonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 501939-94-2P, (5R)-3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-95-3P, (5R)-3-[3-fluoro-4-iodophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-06-6P, 2-fluoro-N'-acetyl-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-3-yl]benzohydrazide 519003-07-7P 519003-08-8P 519003-12-4P 519003-13-5P 519003-15-7P 519003-17-9P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 RN 501939-94-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 519003-08-8 HCAPLUS  
 CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-12-4 HCAPLUS  
 CN Benzenecarbothioamide, 2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-13-5 HCAPLUS  
 CN Benzanide, 2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]- (9CI) (CA INDEX NAME)

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 519003-06-6 HCAPLUS  
 CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]-, 2-acetylhydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 519003-07-7 HCAPLUS  
 CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 519003-15-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[4,5-dihydro-4-hydroxy-4-(trifluoromethyl)-2-thiazolyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-17-9 HCAPLUS  
 CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]-, 2-(cyanoacetyl)hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
 ED Entered STN: 21 Mar 2003  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Oxazolidinones and isoxazolinones (shown as I; variables defined below; e.g. (5S,5S')-N-[3-(4'-[5-(acetylaminomethyl)-2-oxoxazolidin-3-yl]-2,2'-difluorobiphenyl-4-yl)-2-oxoxazolidin-5-ylmethyl]acetamide (shown as II)), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their manufacture and pharmaceutical compns. containing them are described. For I: C is for example III, IV, V, wherein A and B = 2-oxoxazolidin-3-yl, 2-isoxazolin-3-yl; R2a to R3b = H and F; R1a and R1b =, for example, hydroxy, -NHC(=W)R4, NH(HET-1) and HET-2; wherein W is O or S; R4 is, for example, H, amino, (1-4C)alkyl, HET-1 is, for example, a C-linked 5-membered heterocyclic ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsatd. heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as H. influenzae, M. catarrhalis, Mycoplasma and Chlamydia strains. The min. inhibitory concns. of Ii for methicillin sensitive and quinolone sensitive Staphylococcus aureus, methicillin resistant and quinolone resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 µg/mL, resp. Preps. of 64 examples of I and many intermediates are included. For example, I was prepared as follows: (5S)-N-[[3-(3-fluoro-4-iodophenyl)-2-oxoxazolidin-5-yl]methyl]acetamide (0.4 mmol) and Bu4NBr (0.4 mmol) were stirred in a mixture of DMF (0.5 mL) and NMe3 (2 mmol), and degassed by bubbling N. Pd(II) acetate (0.04 mmol) was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms are tabulated:

ACCESSION NUMBER: 2003:221667 HCAPLUS  
 DOCUMENT NUMBER: 138:238171  
 TITLE: Preparation of oxazolidinones and/or isoxazolinones as antibacterial agents  
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Swain, Michael Lingard; Hauck, Sheila Irene; Mills, Stuart Dennett  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 127 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022824	A1	20030320	WO 2002-GB4120	20020909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2459766 AA 20030320 CA 2002-2459766 20020909  
 EP 1427711 A1 20040616 EP 2002-765019 20020909  
 EP 1427711 B1 20050713  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 BR 2002012458 A 20041019 BR 2002-12458 20020909  
 JP 2005507386 T2 20050317 JP 2003-526899 20020909  
 US 2005107435 A1 20050519 US 2003-489266 20020909  
 NZ 531621 A 20050624 NZ 2002-531621 20020909  
 AT 299502 E 20050715 AT 2002-765019 20020909  
 ZA 2004001898 A 20050418 ZA 2004-1898 20040308  
 NO 2004001428 A 20040608 NO 2004-1428 20040405  
 GB 2001-21942 A 20010911  
 GB 2002-15420 A 20020704  
 WO 2002-GB4120 W 20020909  
 PRIORITY APPLN. INFO.:  
 OTHER SOURCE(S): MARPAT 138:238171  
 IT 501940-31-4P, (5R)-5-[[[(tert-Butyldimethylsilyl)oxy]methyl]-3-(4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl)]-1,3-oxazolidin-2-one 501940-39-2P, (5R)-3-[4'-[5-[[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-43-6P, (5R)-3-[4'-[5-[[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate); preparation of oxazolidinones and/or isoxazolinones as antibacterial agents)  
 RN 501940-31-4 HCAPLUS  
 CN 2-Oxazolidinone, 5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]-1,1'-biphenyl-4-yl]-, (5R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




RN 501940-39-2 HCAPLUS

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



RN 501940-43-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



IT 501939-93-1P, (5R,5'R)-4,4'-Bi[5-[(1H-1,2,3-triazol-1-yl)methyl]-2-oxoxazolidin-3-yl]-2,2'-difluorobiphenyl 501939-96-4P, (5R)-3-[2-Fluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-04-1P, N-[[3-[2,2'-Difluoro-4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl]methyl]acetamide 501940-11-0P, (5R)-3-[2,2'-Difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-12-1P, (5R)-3-[2,2'-Difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-26-7P, (5R,5'R)-3-[2,2'-Difluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-29-0P, (SR)-5-(Hydroxymethyl)-3-[4'-[(SR)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-33-6P 501940-37-0P, (SR)-3-[2-Fluoro-4'-[(SR)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-38-1P, (SR)-5-(Hydroxymethyl)-3-[4'-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-41-6P, (SR)-5-(1H-1,2,3-Triazol-1-ylmethyl)-3-[4'-[(SR)-5-(1H-1,2,3-triazol-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-42-7P, (SR)-3-[2-Fluoro-4'-[(SR)-5-(1H-1,2,3-triazol-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-46-1P, (SR)-3-[4'-[(SR)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-48-3P, (SR)-3-[4'-[(SR)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-59-6P, (SR)-3-[2-Fluoro-4'-[(SR)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-74-8P, (SR)-3-[4'-[(SR)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-76-7P, (SR)-3-[4'-[(SR)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-78-9P, (SR)-3-[3-Fluoro-4'-[(SR)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-79-0P, (SR)-3-[3-Fluoro-4'-[(SR)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-83-6P, (SR)-3-[5-[(SR)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]pyrid-2-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-84-7P, (SR)-3-[5-[(SR)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]pyrid-2-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-86-9P, (SR)-3-[3-Fluoro-4'-[(SR)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyrid-5-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-91-6P, (SR)-3-[3-Fluoro-4'-[(SR)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one


RE: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of oxazolidinones and/or isoxazolines as antibacterial agents)

RN 501939-93-1 HCAPLUS  
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 501939-96-4 HCAPLUS  
CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-04-1 HCAPLUS  
CN Acetamide, N-[[[3-[2,2'-difluoro-4'-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4,5-dihydro-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 501940-11-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-12-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)


RN 501940-26-7 HCAPLUS  
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-29-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[4'-[(SR)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-33-6 HCAPLUS  
CN 2-Oxazolidinone, 5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-3-[2'-fluoro-4'-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-37-0 HCAPLUS  
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-38-1 HCAPLUS  
 CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 501940-46-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-48-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-41-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-42-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 501940-59-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-74-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienylphenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-76-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienylphenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 501940-78-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-79-0 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-83-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[5-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]-2-pyridinyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-84-7 HCAPLUS

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 501939-95-3, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-97-3, (5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of oxazolidinones and/or isoxazolines as antibacterial agents)  
 RN 501939-95-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-97-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Oxazolidinone, 3-[5-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]-2-pyridinyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-86-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-91-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 501939-67-9P, (5R)-3-(5-Bromopyrid-2-yl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-69-1P, (5R)-3-(5-Bromopyrid-2-yl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-70-4P, (5R)-3-(4-Iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-73-7P, (5R)-3-(4-Iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-94-2P, (5R)-3-(3-Fluoro-4-(trimethylstannyl)phenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-98-6P, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-19-8P, (5R)-3-[4'-[5-[[[tert-Butyldimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-20-1P, (5R)-3-[4'-[5-[[[tert-Butyldimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-27-8P, (5R)-3-(3-Fluoro-4-(trimethylstannyl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-28-9P, (5R)-3-(3-Fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of oxazolidinones and/or isoxazolines as antibacterial agents)  
 RN 501939-67-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-(5-bromo-2-pyridinyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 501939-69-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-(5-bromo-2-pyridinyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-70-4 HCAPLUS  
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-73-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 501940-19-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxymethyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-20-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxymethyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-27-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 501939-94-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-98-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-28-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN  
ED Entered STN: 03 Dec 2002

AB A series of 5-substituted oxazolidinones with varying substitution at the 5-position of the oxazolidinone ring were synthesized and their in vitro antibacterial activity was evaluated. The compds. demonstrated potent to weak antibacterial activity. A novel compound (PH-027) demonstrated potent antibacterial activity, which is comparable to or better than those of linezolid and vancomycin against antibiotic-susceptible standard and clin. isolated resistant strains of gram-pos. bacteria. Although the presence of the C-5-acetamidomethyl functionality at the C-5 position of the oxazolidinones has been widely claimed and reported as a structural requirement for optimal antimicrobial activity in the oxazolidinone class of compds., our results from this work identified the C-5 triazole substitution as a new structural alternative for potent antibacterial activity in the oxazolidinone class.

ACCESSION NUMBER: 2002:915641 HCAPLUS  
DOCUMENT NUMBER: 138:268234  
TITLE: Synthesis and antibacterial activity of 5-substituted oxazolidinones  
AUTHOR(S): Phillips, O. A.; Udo, E. E.; Ali, A. A. M.; Al-Hassawi, N.  
CORPORATE SOURCE: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Kuwait University, Safat, 13110, Kuwait  
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(1), 35-41  
CODEN: BMCEEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 138:268234


IT 503026-25-3P  
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis and antibacterial activity of 5-substituted oxazolidinones)  
RN 503026-25-3 HCAPLUS  
CN 2-Oxazolidinone, 5-[[4-(acetyl-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (synthesis and antibacterial activity of 5-substituted oxazolidinones)  
RN 503026-26-4 HCAPLUS  
CN 2-Oxazolidinone, 5-[[5-(acetyl-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 503026-28-6P 503026-29-7P  
RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation) (synthesis and antibacterial activity of 5-substituted oxazolidinones)  
RN 503026-28-6 HCAPLUS  
CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
IT 503026-27-5P 503090-32-2P, PH 027  
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and antibacterial activity of 5-substituted oxazolidinones)  
RN 503026-27-5 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[1-(methoxymino)ethyl]-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 503090-32-2 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 503026-26-4P

L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A



RN 503026-29-7 HCAPLUS  
CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 Na

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
ED Entered STN: 18 Oct 2002  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [I; HET = N-linked 5-membered, fully or partially unsatd. heterocyclic ring, or an N-linked 6-membered di-hydro-heterocyclic ring; Q = II, III, etc. (wherein R<sub>2</sub>, R<sub>3</sub> = H, F; T = IV, V, etc.)] and their pharmaceutically-acceptable salts, useful in production of an antibacterial effect in a warm blooded animal, were prepared E.g., detailed multi-step synthesis of (SR)-VI as its mesitylene sulfonate salt, starting from 3,5-difluoroaniline and tetrahydrothiopyran-4-one, was described. Antibacterial properties of compound VI were tested against 5 different bacteria, and its MIC values were given.

ACCESSION NUMBER: 2002:793623 HCAPLUS  
DOCUMENT NUMBER: 137:310923  
TITLE: Preparation of oxazolidinones substituted by novel sulfilimine and sulfoximine-containing rings as antibiotics  
INVENTOR(S): Betts, Michael John; Swain, Michael Lingard; Hales, Neil James; Ruyh, Hoan Khai  
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
SOURCE: PCT Int. Appl., 106 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081470	A1	20021017	WO 2002-GB1644	20020403
W: AK, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1385844	A1	20040204	EP 2002-720195	20020403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531518	T2	20041014	JP 2002-579458	20020403
US 2005032861	A1	20050210	US 2004-480959	20040628
PRIORITY APPLN. INFO.:			GB 2001-8765	A 20010407
			US 2001-330588P	P 20011025
			WO 2002-GB1644	W 20020403

OTHER SOURCE(S): MARPAT 137:310923  
IT 471913-40-3P 471913-42-5P 471913-43-6P  
471913-46-9P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

(Preparation); RACT (Reactant or reagent); USES (Uses)  
(Prepn. of oxazolidinones substituted by novel sulfilimine and sulfoximine-contg. rings as antibiotics)  
RN 471913-40-3 HCAPLUS  
CN 2H-Thiopyran, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-1-imino-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471913-42-5 HCAPLUS  
CN Benzenesulfonic acid, 2,4,6-trimethyl-, compd. with (5R)-3-[4-(1,1,3,6-tetrahydro-1-imino-2-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-2-oxazolidinone (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 471913-41-4  
CMF C17 H17 F2 N5 O3 S


Absolute stereochemistry.



L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CH 2

CRN 3453-83-6  
CMF C9 H12 O3 S



RN 471913-43-6 HCAPLUS  
CN Thiomorpholine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-1-imino-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471913-46-9 HCAPLUS  
CN Thiomorpholine, 1-[(cyanoimino)(methylthio)methyl]imino-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 471913-44-7P 471913-45-8P 471913-47-0P

471913-48-1P 471913-49-2P 471913-50-5P

471913-51-6P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolidinones substituted by novel sulfilimine and sulfoximine-containing rings as antibiotics)


RN 471913-44-7 HCAPLUS

CN Thiomorpholine, 4-[[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-1-(methylimino)-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 471913-49-2 HCAPLUS

CN 2H-Thiopyran, 1-(acetylimino)-4-[[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471913-50-5 HCAPLUS

CN 2H-Thiopyran, 1-(acetylimino)-4-[[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 471913-45-8 HCAPLUS

CN Thiomorpholine, 4-[[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-1-[(1H-imidazol-2-ylmethyl)imino]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471913-47-0 HCAPLUS

CN Thiomorpholine, 1-[[[(cyanomino)(dimethylamino)methyl]imino]-4-[[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 471913-48-1 HCAPLUS

CN Thiomorpholine, 1-[[[4-amino-5-(methoxycarbonyl)-2-thiazolyl]imino]-4-[[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 471913-51-6 HCAPLUS

CN 2H-Thiopyran, 4-[[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,1,3,6-tetrahydro-1-[(hydroxyacetyl)imino]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 371195-00-5P 371195-01-6P 371195-03-8P

371195-04-9P 471913-52-7P 471913-53-8P

471913-54-9P


RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazolidinones substituted by novel sulfilimine and sulfoximine-containing rings as antibiotics)

RN 371195-00-5 HCAPLUS


L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-01-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-03-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 471913-53-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471913-54-9 HCAPLUS  
 CN 2H-Thiopyran, 1-[[[(acetyloxy)acetyl]imino]-4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-04-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471913-52-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 02 Nov 2001  
 GI



AB The title compds. [I: X = O, NH, S, etc.; HET = (un)substituted C-linked 5-membered heterocyclic ring containing 2-4 heteroatoms selected from N, O and S, etc.; Q = II, III, etc. (wherein R2, R3 = H, F; T = an N-linked (fully unsatd.) 5-membered heterocyclic ring system or IV; R = R1CO, R13SO2, R13CS, etc.; R13 = alkyl, etc.)], useful as antibacterial agents, were prepared and formulated. E.g., a multi-step synthesis of the oxazoline (R)-V which showed MIC of 0.125 µg/mL against *Staphylococcus aureus* (Oxford), was given.


ACCESSION NUMBER: 2001:798227 HCAPLUS  
 DOCUMENT NUMBER: 135:344473  
 TITLE: Oxazolidinone derivatives with antibacterial activity  
 INVENTOR(S): Gravestock, Michael Barry; Betts, Michael John; Griffin, David Alan; Matthews, Ian Richard  
 PATENT ASSIGNEE(S): AstraZeneca AB, Sued.; AstraZeneca UK Limited  
 SOURCE: PCT Int. Appl., 143 pp.  
 DOCUMENT TYPE: CODEN: PINKD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English  
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081350	A1	20011101	WO 2001-GB1815	20010423
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BU, CA, CH, CY, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, DE, DR, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2405349 AA 20011101 CA 2001-2405349 20010423  
 BR 2001010240 A 20030107 BR 2001-10240 20010423  
 EP 1286998 A1 20030305 EP 2001-921669 20010423  
 EP 1286998 B1 20040609  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2003531211 T2 20031021 JP 2001-578439 20010423  
 EE 200200598 A 20040415 EE 2002-598 20010423  
 NZ 521765 A 20040528 NZ 2001-521765 20010423  
 AT 268778 E 20040615 AT 2001-921669 20010423  
 PT 1286998 T 20040930 PT 2001-921669 20010423  
 ES 2220759 T3 20041216 ES 2001-1921669 20010423  
 AU 781784 B2 20050616 AU 2001-48636 20010423  
 ZA 2002008187 A 20040211 ZA 2002-8187 20021010  
 WO 2002005091 A 20021209 WO 2002-5091 20021023  
 US 2003216373 A1 20031120 US 2003-258355 20030506  
 HK 1053114 A1 20050218 HK 2003-105394 20030725  
 GB 2000-9803 A 20000425  
 WO 2001-GB1815 W 20010423

PRIORITY APPL. INFO.:  
 OTHER SOURCE(S): MARPAT 135:344473  
 IT 371194-18-2P 371194-19-3P 371194-20-6P  
 371194-23-9P 371194-26-2P 371194-34-2P  
 371194-35-3P 371194-37-5P 371194-39-7P  
 371194-42-2P 371194-57-9P 371194-63-7P  
 371194-67-1P 371194-69-3P 371194-71-7P  
 371194-73-9P 371194-75-1P 371195-01-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (oxazolidinone derivs. with antibacterial activity)  
 RN 371194-18-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-19-3 HCAPLUS  
 CN 4-Piperidinone, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-20-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(4-amino-1-piperidinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-23-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-methylamino)-1-piperidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-26-2 HCAPLUS  
 CN Acetamide, 2-(acetyloxy)-N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-34-2 HCAPLUS  
 CN Carbamic acid, [(3R)-1-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 371194-35-3 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(3R)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-37-5 HCAPLUS  
 CN Carbanic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-39-7 HCAPLUS  
 CN Carbanic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-67-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371194-69-3 HCAPLUS  
 CN Pyridine, 1-[(acetyloxy)acetyl]-4-[2,6-difluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-42-2 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(3S)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 371194-57-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(methylthio)phenyl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-63-7 HCAPLUS

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-71-7 HCAPLUS  
 CN Pyridine, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-[[4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-73-9 HCAPLUS  
 CN Pyridine, 1-[(acetyloxy)acetyl]-4-[2,6-difluoro-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-75-1 HCAPLUS  
 CN Pyridine, 1-[[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-01-6 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-22-8 HCAPLUS  
 CN Carbamic acid, [1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-24-0 HCAPLUS  
 CN Methanesulfonamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 371194-21-7P 371194-22-8P 371194-24-0P  
 371194-25-1P 371194-27-3P 371194-28-4P  
 371194-29-5P 371194-30-8P 371194-31-9P  
 371194-32-0P 371194-33-1P 371194-36-4P  
 371194-38-6P 371194-40-0P 371194-41-1P  
 371194-43-3P 371194-44-4P 371194-45-5P  
 371194-46-6P 371194-58-0P 371194-59-1P  
 371194-62-6P 371194-64-8P 371194-65-9P  
 371194-66-0P 371194-68-2P 371194-70-6P  
 371194-72-8P 371194-74-0P 371194-76-2P  
 371194-94-4P 371194-95-5P 371194-96-6P  
 371194-97-7P 371194-98-8P 371194-99-9P  
 371195-00-5P 371195-02-7P 371195-03-8P  
 371195-04-9P 371195-17-4P 371195-18-5P  
 371195-19-6P 371195-20-9P 371195-21-0P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (oxazolidinone derivs. with antibacterial activity)

RN 371194-21-7 HCAPLUS  
 CN Methanesulfonamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-25-1 HCAPLUS  
 CN Carbamic acid, [1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-27-3 HCAPLUS  
 CN Acetamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-28-4 HCAPLUS  
 CN Piperazine, 1-[(2S)-2,3-dihydroxy-1-oxopropyl]-4-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-29-5 HCAPLUS  
 CN Piperazine, 1-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 371194-32-0 HCAPLUS  
 CN Piperazine, 1-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-4-[(2-methoxyethyl)methylamino]acetyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-33-1 HCAPLUS  
 CN Piperazine, 1-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-4-[(2-methoxyethyl)amino]acetyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 371194-30-8 HCAPLUS  
 CN Piperazine, 1-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-4-[(2-hydroxyethyl)methylamino]acetyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-31-9 HCAPLUS  
 CN Acetamide, N-[2-[[2-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-1-piperazinyl]-2-oxoethyl]amino]ethyl]-

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 371194-36-4 HCAPLUS  
 CN Carbamic acid, [(3R)-1-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-38-6 HCAPLUS  
 CN Carbamic acid, [(3R)-1-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-3-pyrrolidinyl]-, (2S)-2,3-dihydroxypropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-40-0 HCAPLUS  
 CN Carbamic acid, [(3R)-1-[(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-

# Ngrazier 10671326Amend2


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 2-hydroxyethyl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-41-1 HCAPLUS  
CN Carbamic acid, [(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-43-3 HCAPLUS  
CN Acetamide, N-[(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-44-4 HCAPLUS  
CN Carbamic acid, [(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-59-1 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-(1,1-dimethylethyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-62-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 371194-45-5 HCAPLUS  
CN Methanesulfonamide, N-[(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-46-6 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-58-0 HCAPLUS  
CN 2-Oxazolidinone, 3-[4-(methylsulfonyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-64-8 HCAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-65-9 HCAPLUS  
CN 1(2H)-Pyridinecarboxaldehyde, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-66-0 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1H-1,2,3-triazol-1-ylmethyl)-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-68-2 HCAPLUS  
 CN 1(2H)-Pyridinecarboxaldehyde, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,6-dihydro-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-74-0 HCAPLUS  
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-76-2 HCAPLUS  
 CN Pyridine, 1-[(2S)-2,3-dihydroxy-1-oxopropyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-70-6 HCAPLUS  
 CN Pyridine, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-72-8 HCAPLUS  
 CN Pyridine, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-94-4 HCAPLUS  
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(1-methylethyl)sulfonyl]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-95-5 HCAPLUS  
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(methylsulfonyl)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-96-6 HCAPLUS  
 CN Pyridine, 1-(ethylsulfonyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-97-7 HCAPLUS  
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-00-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-02-7 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-98-8 HCAPLUS  
 CN Pyridine, 1-[(3-chloropropyl)sulfonyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-99-9 HCAPLUS  
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(2-methoxyethyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-03-8 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-04-9 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-17-4 HCAPLUS  
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(4-morpholinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371195-18-5 HCAPLUS  
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-hydroxyethyl)methylamino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 371195-21-0 HCAPLUS  
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-methoxyethyl)methylamino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 371196-57-5  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (oxazolidinone derivs. with antibacterial activity)

RN 371196-57-5 HCAPLUS  
 CN 2-Oxazolidinone, 3-[4-[(3R)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 16929/11/2005


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 371195-19-6 HCAPLUS  
 CN Acetamide, N-[2-[[2-[4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl]amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371195-20-9 HCAPLUS  
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-methoxyethyl)methylamino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

IT 371195-29-8P 371195-30-1P 371195-31-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (oxazolidinone derivs. with antibacterial activity)  
 RN 371195-29-8 HCAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-30-1 HCAPLUS  
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 371195-31-2 HCAPLUS  
 CN Piperazine, 1-[[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-4-[2-fluoro-4-[[[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-9CI] (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 20 Aug 1989  
 GI



AB The synthesis and structure/activity studies of the effect of varying the B group in a series of oxazolidinone antibacterials I (R = Me2CH, Me, SO2, Ac, etc.; R1 = B = H, Me, OH, NHAc, etc.) are described. Two synthetic routes were used (1) alkylation of aniline with glycidol followed by dialkyl carbonate heterocyclization to afford I (R = H, R1 .tpbond. B = OH), whose arene ring was further elaborated by using electrophilic aromatic substitution methodol.; (2) cycloaddn. of substituted aryl isocyanates with epoxides. I with B = OH or Br were converted to other B functionalities by using SN2 methodol. Antibacterial evaluation of compds. I with R = acetyl, iso-Pr, methylthio, methylsulfinyl, methylsulfonyl, and sulfonamido and a variety of different B groups against Staphylococcus aureus and Enterococcus faecalis concluded that the compds. with B = aminoacyl, and particularly acetamido, were the most active of those examined in each R series, possessing MIC's in the range of 0.5-4 µg/mL for the most active compds. described.

ACCESSION NUMBER: 1989:457600 HCAPLUS  
 DOCUMENT NUMBER: 111:57600  
 TITLE: Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxazolidinones. 1. The B group  
 AUTHOR(S): Gregory, Walter A.; Brittelli, David R.; Wang, C. L. J.; Wuonola, Mark A.; McRipley, Ronald J.; Eustice, David C.; Eberly, Virginia S.; Slee, Andrew M.; Forbes, Martin; Bartholomew, P. T.  
 CORPORATE SOURCE: Exp. Stn., E. I. du Pont de Nemours and Co., Wilmington, DE, 19898, USA  
 SOURCE: Journal of Medicinal Chemistry (1989), 32(8), 1673-81  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 111:57600  
 IT 121372-95-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and bactericidal activity of)

RN 121372-95-0 HCAPLUS  
 CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[[[3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-, dimethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

